Clinical Study Report mRNA-1273-P201 Addendum 1

mRNA-1273

16.2.7 Adverse Event Listings (Each Participant)

Listing 16.2.7.7	Unsolicited Adverse Events Safety Set
Listing 16.2.7.8	Serious Adverse Events Safety Set
Listing 16.2.7.10	Unsolicited Adverse Events Leading to Discontinuation from Participation in the Study Safety Set
Listing 16.2.7.11	Unsolicited Medically-Attended Adverse Events Safety Set
Listing 16.2.7.12	Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Page 1 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) / End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011056; Age (Ye Reproductive system and breast disorders/ Testicular cyst/ BENIGN CYST, LEFT TESTICLE	ears): 30; Gender: M; 2020-09-05 (68)/ ONGOING	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2011060; Age (Yes Skin and subcutaneous tissue disorders/ Dermatitis contact/ EXASPERATION OF POISON IVY RASH LEFT FOREARM/RIGHT UPPER THIGH	ears): 49; Gender: F; 2020-06-06 (5)/ 2020-06-13 (12)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Toothache/ TOOTH PAIN, LEFT LOWER SECOND MOLAR (FROM ROOT CANAL)	2020-07-23 (24)/ 2020-07-30 (31)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 2 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011064; Age (Ye	ears): 34; Gender: F;	Race: W	HITE				
Skin and subcutaneous	2020-07-24 (24)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
tissue disorders/	2020-08-06 (37)	No/				CONCOMITANT	RESOLVED
Dermatitis contact/		No				MEDICATION	
POISON OAK LEFT ARM							
Subject ID: US2011067; Age (Ye	ears): 28; Gender: F;	Race: B	BLACK C	R AFRICAN	AMERICAN		
Respiratory, thoracic and	2020-06-09 (7)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
mediastinal disorders/	2020-07-17 (45)	Yes/				CHANGED/	RESOLVED
Cough/		No				NONE	
COUGH							
Respiratory, thoracic and	2020-06-09 (7)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
mediastinal disorders/	2020-07-30 (58)	Yes/				CHANGED/	RESOLVED
Dry throat/	(,	No				NONE	
DRY THROAT							

Notes listed on the last page.

Page 3 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	′ Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011067; Age (Y	Mears): 28; Gender: F;	Race: E	BLACK C	R AFRICAN	AMERICAN		
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-11-06 (123)/ 2020-11-15 (132)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-11-06 (123)/ 2020-11-16 (133)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pain/ BODY ACHES	2020-11-07 (124)/ 2020-11-15 (132)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 4 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) End Date and Time (Relative Day)	cited		SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011067; Age (Y Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RUNNY NOSE	2020-11-08 (125)/	Race: Yes/ Yes/ No	BLACK C	OR AFRICAN No	AMERICAN NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011068; Age (Y General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	<pre>'ears): 44; Gender: M 2020-06-30 (1)/ 2020-07-15 (16)</pre>	Race: Yes/ No/ Yes	WHITE 1	No	R/R	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site bruising/ BRUISE AT INJECTION SITE	2020-06-30 10:50 (1 2020-07-17 (18))/Yes/ No/ No	1	No	NR/R	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 5 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011068; Age General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	(Years): 44; Gender: M; 2020-07-01 14:00 (2) 2020-07-10 23:00 (11	/ Yes/	HITE 1	No	R/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011088; Age Infections and infestations/ Hordeolum/ STYE, LEFT EYE	(Years): 47; Gender: M; 2020-07-18 (12)/ 2020-07-25 (19)	Race: WI Yes/ No/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Tendon injury/ LEFT LACERATED GREAT TOE TENDON	2021-01-15 (193)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 6 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021062; Age (Y Injury, poisoning and procedural complications/ Muscle strain/ MUSCLE STRAIN LEFT HAMSTRIN	2020-06-09 (6)/ 2020-06-16 (13)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Lethargy/ LETHARGY	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Sinus congestion/ SINUS CONGESTION	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 7 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021062; Age (Young Musculoskeletal and connective tissue disorders/ Myalgia/ MYALGIA GENERALIZED	ears): 44; Gender: M; 2020-06-25 (22)/ 2020-06-28 (25)	Race: Will Yes/ No/ No	HITE 2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021073; Age (YGASTROINTESTINAL DISORDERS/OTAL DISORDERS/OTAL DISORDERS/OTAL DESIGN ON GUM (UNKNOWN) BENGIN	•	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-12-05 (159)/ 2020-12-20 (174)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 8 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021082; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 47; Gender: M; 2020-09-06 (62)/ 2020-09-11 (67)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2020-09-10 (66)/ 2020-10-08 (94)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood testosterone decreased/ LOW TESTOSTERONE	2020-10-15 (101)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 9 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021082; Age (Y Investigations/ Vitamin D decreased/ LOW VITAMIN D	<pre>/ears): 47; Gender: M; 2020-10-17 (103)/ ONGOING</pre>	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Endocrine disorders/ Hyperoestrogenism/ HYPERESTROGENISM	2020-12-14 (161)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
ubject ID: US2021094; Age ()	Mears): 53; Gender: M;	Race: W	HITE				
Respiratory, thoracic and mediastinal disorders/Cough/COUGH	2020-06-26 (22)/ 2020-08-08 (65)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Sinus headache/ SINUS HEADACHE	2020-06-29 (25)/ 2020-07-01 (27)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 10 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021094; Age (Y Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	Tears): 53; Gender: M; 2020-07-06 (32)/ 2020-07-23 (49)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021096; Age (Yes) General disorders and administration site conditions/ Fatigue/ FATIGUE	Years): 25; Gender: F; 2020-07-08 (7)/2020-07-10 (9)	Race: Wi Yes/ No/ Yes	HITE 3	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021107; Age (Y Nervous system disorders/ Headache/ HEADACHE		Race: A Yes/ No/ No	SIAN 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 11 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021107; Age (Y Respiratory, thoracic and mediastinal disorders/ Nasal congestion/ NASAL CONGESTION	ears): 26; Gender: F; 2020-09-02 (63)/ 2020-09-05 (66)	Race: As Yes/ No/ No	SIAN 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021111; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 36; Gender: F; 2020-07-10 (33)/ 2020-07-17 (40)	Race: Will Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-07-12 (35)/ 2020-07-14 (37)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 12 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021111; Age (Year Respiratory, thoracic and mediastinal disorders/Cough/COUGH	ears): 36; Gender: F; 2020-07-12 (35)/ 2020-07-16 (39)	Race: WH Yes/ No/ No	HITE 2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-12 (35)/ 2020-07-18 (41)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-13 (36)/ 2020-07-19 (42)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Suspected COVID-19/ COVID 19 LIKE ILLNESS	2021-01-20 (184)/ 2021-01-25 (189)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 13 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021111; Age Musculoskeletal and connective tissue disorders/ Bursitis/ BURSITIS LEFT SHOULDER	(Years): 36; Gender: F; 2021-02-01 (196)/ 2021-02-08 (203)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021137; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	(Years): 26; Gender: M; 2020-07-07 15:39 (29) 2020-07-15 14:00 (37	/Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021138; Age Infections and infestations/ Suspected COVID-19/ COVID 19 LIKE ILLNESS	(Years): 52; Gender: F; 2021-02-06 (216)/ 2021-02-17 (227)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 14 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021144; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES ALL OVER BODY	Tears): 18; Gender: F; 2020-06-06 20:12 (2), 2020-06-14 07:12 (9)		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-06 20:12 (2), 2020-06-14 07:48 (9)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-06-09 (5)/ 2020-06-14 (10)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 15 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)			SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021155; Age (Infections and infestations/ COVID-19/ COVID-19 INFECTION	Years): 46; Gender: M; 2020-08-17 (36)/ 2020-09-23 (73)			No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2021175; Age (General disorders and administration site conditions/ Fatigue/ FATIGUE	Years): 36; Gender: F; 2020-07-08 21:31 (1), 2020-07-17 14:13 (10)	/ Yes/		No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-08-02 (26) / 2020-08-02 (26)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 16 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021175; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 36; Gender: F; 2020-10-12 (97)/ 2020-11-01 (117)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031029; Age Renal and urinary disorders/ Hypertonic bladder/ OVER ACTIVE BLADDER	(Years): 40; Gender: F; 2020-06-17 (16)/ 2020-07-14 (43)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-08-04 (29)/ 2020-08-10 (35)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 17 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031041; Age (Y Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-07-05 (5)/ 2020-07-11 (11)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Neuralgia/ RIGHT FOOT NERVE PAIN	2021-01-27 (211)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2031049; Age (Y	ears): 37; Gender: F;	Race: W	HITE				
Psychiatric disorders/ Anxiety/ ANXIETY	2020-12-08 (161)/ 2021-02-02 (217)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 18 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR		SAE/ Criteria	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
				[2]	11/01 [0]	Taken	Odecome
Subject ID: US2031049; Age Psychiatric disorders/ Depression/ DEPRESSION	2020-12-08 (161)/ 2021-02-02 (217)	Yes/ Yes/ No	1 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031074; Age	(Years): 52; Gender: F;	Race:	WHITE				
Infections and infestations/ Otitis media/ BILATERAL ACUTE OTITIS MED	2020-06-10 (9)/ 2020-06-19 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Sinusitis/ SINUS INFECTION	2020-06-10 (9)/ 2020-06-19 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-06-30 22:00 (1) 2020-07-08 18:00 (9)		1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 19 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/	Start Date and Time (Relative Day)/ End Date and	cited	Sev.	SAE/ Criteria	-	Action Taken with IP/ Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2031074; Age (Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	(Years): 52; Gender: F; 2021-02-05 (221)/ 2021-02-15 (231)	Race: Yes/ Yes/ No	WHITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031081; Age (Infections and infestations/COVID-19/COVID 19 INFECTION	(Years): 36; Gender: F; 2020-08-03 (33)/ 2020-08-03 (33)	Race: Yes/ No/ No	WHITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041005; Age ((Years): 22; Gender: F;	Race:	WHITE				
Nervous system disorders/ Headache/ HEADACHE	2020-10-12 (109)/ 2020-10-15 (112)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Lethargy/ LETHARGY	2020-10-12 (109)/ 2020-10-15 (112)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 20 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041019; Age (Yangury, poisoning and procedural complications/Skin laceration/LEFT HAND LACERATION	2020-07-06 (7)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2041022; Age (Y Infections and infestations/ COVID-19/ COVID-19 INFECTION	Years): 40; Gender: F; 2020-10-31 (118)/ 2020-11-15 (133)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041056; Age (Y Skin and subcutaneous tissue disorders/ Acne/ GENERALIZED ACNE	Years): 23; Gender: M; 2021-02-08 (224)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 21 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/	Start Date and Time (Relative Day)/	MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria		Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2051022; Age (Ye	ears): 22; Gender: F;	Race: W	HITE				
Gastrointestinal disorders/ Odynophagia/ ODYNOPHAGIA	2020-07-28 (22)/ 2020-08-04 (29)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Localised infection/ TOE INFECTION RIGHT FOOT (2-4 DIGITS)	2020-12-04 (151)/ 2021-01-14 (192)	Yes/ Yes/ No	2	No	R/R	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051035; Age (Ye Infections and infestations/COVID-19/POSITIVE COVID 19 INFECTION	ears): 20; Gender: F; 2020-09-03 (58)/ 2021-03-26 (262)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 22 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051036; Age Skin and subcutaneous tissue disorders/ Acne/ ACNE VULGARIS ON BACK	(Years): 49; Gender: M; 2020-07-23 (22)/ 2021-02-04 (218)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061003; Age Infections and infestations/ COVID-19/ COVID - 19 INFECTION	(Years): 35; Gender: F; 2021-01-06 (185)/ 2021-01-16 (195)		HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061018; Age Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTI	2020-11-28 (144)/ 2020-12-01 (147)		HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 23 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited S	Sev. C	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061018; Age (Yange Infections and infestations/ COVID-19/ COVID-19 POSITIVE INFECTION	2020-12-01 (147)/ 2020-12-05 (151)			No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061021; Age (Y Investigations/ Heart rate decreased/ DECREASED HEART RATE	· · · · · · · · · · · · · · · · · · ·			No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061024; Age (Y Respiratory, thoracic and mediastinal disorders/ Dyspnoea/ SHORTNESS OF BREATH - NOS	2020-11-25 (147)/			No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 24 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071012; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 40; Gender: F; 2020-12-04 (151)/ 2020-12-16 (163)	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071044; Age Metabolism and nutrition disorders/ Vitamin D deficiency/ VITAMIN D DEFICIENCY	(Years): 32; Gender: F; 2021-01-28 (204)/ ONGOING	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071050; Age Infections and infestations/ Gingivitis/ GINGIVITIS	(Years): 45; Gender: M; 2020-12-04 (151)/ 2020-12-14 (161)	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 25 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071050; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 45; Gender: M; 2020-12-04 (151)/ 2020-12-18 (165)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071062; Age Skin and subcutaneous tissue disorders/ Rash/ RASH ON GLUTEUS	(Years): 29; Gender: M; 2020-06-05 (2)/ 2020-06-06 (3)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2020-11-24 (141)/ 2020-11-30 (147)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 26 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/	Start Date and Time (Relative Day)/ End Date and	TEAE/ MAAE/ Soli- cited	Sev.	SAE/ Criteria	Relation- ship to	Action Taken with IP/ Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071066; Age (Y Gastrointestinal disorders/Diverticulum/DIVERTICULOSIS			HITE 1	No	NR/NR	NOT APPLICABLE/CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERING/ RESOLVING
Subject ID: US2071070; Age (Y Infections and infestations/ COVID-19/ COVID 19 INFECTION	ears): 34; Gender: F; 2020-12-11 (158)/ 2021-02-02 (211)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071072; Age (Y Infections and infestations/ COVID-19/ COVID 19 INFECTION	ears): 39; Gender: F; 2020-11-30 (148)/ 2020-12-11 (159)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 27 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081033; Age (YINTERCOMMENT) Infections and infestations/ Otitis externa/ SWIMMER'S EAR (LEFT EAR)	Years): 43; Gender: F; 2020-07-13 (7)/ 2020-07-18 (12)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2021-01-05 (183)/ 2021-03-15 (252)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081038; Age (Yangury, poisoning and procedural complications/Skin laceration/CUT ON LEFT FOREARM	2020-06-08 14:00 (1)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 28 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081042; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 49; Gender: F; 2020-07-09 12:00 (2) 2020-07-10 12:00 (3)	/ Yes/	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081046; Age Skin and subcutaneous tissue disorders/ Rash papular/ PAPULAR RASH ON FOREARM (BILATERAL)	(Years): 45; Gender: M; 2020-06-08 (1)/ 2020-06-16 (9)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 29 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]		Outcome
Subject ID: US2081046; Age (Infections and infestations/COVID-19/CONFIRMED COVID 19 INFECTION (SYMPTOMATIC- FEVER, HEADACHE, HEAVY FEELING IN CHEST, BODY ACHES)	2020-10-06 (90)/ 2020-11-06 (121)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081049; Age (Infections and infestations/Gastroenteritis/GASTROENTERITIS	Years): 47; Gender: F; 2020-07-17 (10)/ 2020-07-28 (21)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-27 (20)/ 2020-08-03 (27)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 30 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					_
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081049; Age (Years): 47; Gender: F;	Race: WI	HITE				
Infections and	2020-08-05 (29)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
infestations/	2020-08-12 (36)	Yes/				CONCOMITANT	RESOLVED
Oral candidiasis/		No				MEDICATION	
THRUSH (TONGUE)							
Psychiatric disorders/	2020-11-17 (133)/	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
Anxiety/	2020-12-22 (168)	Yes/				CONCOMITANT	RESOLVED
WORSENING OF ANXIETY		No				MEDICATION	
Subject ID: US2081058; Age (Years): 20; Gender: F;	Race: WI	HITE				
Infections and	2020-11-16 (162)/	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
infestations/	2020-12-02 (178)	Yes/				NONE	RESOLVED
Sinusitis/		No					
SINUS INFECTION							

Notes listed on the last page.

Page 31 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011051; Age (Y Skin and subcutaneous tissue disorders/ Rash/ ALL OVER BODY RASH	Years): 20; Gender: F; 2020-06-22 (21)/ 2020-07-02 (31)	Race: WI Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/Rhinorrhoea/RUNNY NOSE	2020-10-15 (102)/ 2020-10-25 (112)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Sneezing/ SNEEZING	2020-10-16 (103)/ 2020-10-22 (109)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Dizziness/ LIGHTHEADEDNESS	2020-10-17 (104)/ 2020-10-20 (107)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 32 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		T	'EAE/					
	Start Date and		IAAE/		,		Action Taken	
System Organ Class/	Time (Relative D	_	oli-	_	SAE/	Relation-	with IP/	
Preferred Term/	End Date and			Sev.	Criteria	-	Other Action	
/erbatim	Time (Relative D	ay) A	.R	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011051; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	Tears): 20; Gender 2020-10-17 (104) 2020-10-28 (115)	/ Y	es/ es/	ITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Ageusia/ LOSS OF TASTE	2020-10-17 (104) 2020-10-30 (117)		es/ es/ lo	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Dizziness/ DIZZINESS	2020-10-18 (105) 2020-10-23 (110)		es/	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pain/ BODY ACHES	2020-10-18 (105) 2020-10-28 (115)		es/	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 33 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (Ye Respiratory, thoracic and mediastinal disorders/Cough/COUGH		Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-10-19 (106)/ 2020-10-28 (115)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/Road traffic accident/CAR ACCIDENT	2020-11-19 (137)/ 2020-11-19 (137)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Post-traumatic pain/ BACK PAIN, SECONDARY TO CAR ACCIDENT	2020-11-19 (137)/ 2020-12-15 (163)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 34 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (You Injury, poisoning and procedural complications/Post-traumatic pain/NECK PAIN SECONDARY TO CAR ACCIDENT	2020-11-19 (137)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011055; Age (Yo Gastrointestinal disorders/ Nausea/ NAUSEA		Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES, ALL OVER BODY	2020-06-21 (20)/ 2020-06-24 (23)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 35 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011084; Age (Yes Skin and subcutaneous tissue disorders/Dermatitis contact/MACULOPAPULAR RASH ON CHESTAND ABDOMEN, ALLERGIC REACTION TO NEW SOAP	2020-07-01 06:00 (1), 2020-07-13 (14)		HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2011087; Age (Y Psychiatric disorders/ Anxiety/ ANXIETY	•	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Psychiatric disorders/ Insomnia/ TROUBLE SLEEPING, DUE TO ANXIETY	2021-01-01 (185)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 36 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011091; Age (You Vascular disorders/ Hypertension/ HYPERTENSION	ears): 54; Gender: F; 2020-10-05 (96)/ ONGOING	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Respiratory, thoracic and mediastinal disorders/ Dyspnoea/ SHORTNESS OF BREATH	2020-11-19 (141)/ 2020-11-21 (143)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-11-19 (141)/ 2020-11-21 (143)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-11-19 (141)/ 2020-11-23 (145)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 37 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011091; Age (General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 54; Gender: F; 2020-11-19 (141)/ 2020-11-23 (145)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/Chills/CHILLS	2020-11-21 (143)/ 2020-11-22 (144)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011092; Age (Gastrointestinal disorders Gastritis/ GASTRITIS		Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 38 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011092; Age Infections and infestations/ Bronchitis/ BRONCHITIS	(Years): 40; Gender: F; 2020-11-20 (137)/ 2020-12-02 (149)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011095; Age General disorders and administration site conditions/ Injection site bruising/ BRUISE AT INJECTION SITE	(Years): 26; Gender: F; 2020-06-06 (2)/ 2020-06-20 (16)	Race: W Yes/ No/ No	HITE 1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Arthralgia/ PAIN IN LEFT HIP	2020-06-09 (5)/ 2020-06-09 (5)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 39 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011095; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ PAIN IN LEFT HIP	ears): 26; Gender: F; 2020-06-10 (6)/ 2020-06-10 (6)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Dermatitis contact/ RASH, UPPER RT HIP (LIKELY DUE TO POISON IVY CONTACT)	2020-06-27 (23)/ 2020-07-12 (38)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Ear and labyrinth disorders/ Deafness unilateral/ HEARING LOSS, LEFT EAR	2020-11-17 (135)/ ONGOING	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 40 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011102; Age (Y Injury, poisoning and procedural complications/ Meniscus injury/ TORN MINISCUS, LEFT KNEE	2020-09-01 (58)/	Race: WH Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/Procedural pain/POST-OPERATIVE PAIN, TORN LEFT KNEE MENISCUS	2020-11-30 (148)/ 2020-12-07 (155)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021058; Age (Y	•				- /		
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOIN	2020-07-07 19:00 (1), 2020-07-14 22:22 (8)	No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 41 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021058; Age (Yellow) General disorders and administration site conditions/ Pain/ GENERALIZED BODY ACHES	Years): 24; Gender: F; 2020-07-07 19:00 (1) 2020-07-14 22:22 (8)		HITE 3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-07 21:41 (1) 2020-07-15 12:00 (9)		3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Joint swelling/ SWELLING AT PROXIMAL JOINT 2ND DIGIT RIGHT HAND	2020-07-08 20:00 (2) ONGOING	/Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 42 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021058; Age (Y Nervous system disorders/ Headache/ HEADACHES	Tears): 24; Gender: F; 2020-07-14 (8)/ 2020-07-15 (9)	Race: Windows	HITE 2	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Tooth fracture/ BROKEN TOOTH RIGHT MOLAR	2020-07-22 (16)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2021064; Age (Y Nervous system disorders/ Headache/ HEADACHE	•	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-06 (29)/ 2020-07-06 (29)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 43 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021064; Age (Y General disorders and administration site conditions/ Chest discomfort/ CHEST PRESSURE	Tears): 54; Gender: F; 2020-07-06 (29)/ 2020-07-06 (29)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Nasal pruritus/ ITCHY NOSE	2020-07-06 (29)/ 2020-07-08 (31)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021084; Age (Y Skin and subcutaneous tissue disorders/ Rash/ RASH RIGHT ELBOW	Years): 34; Gender: M; 2020-07-08 08:00 (1), 2020-07-13 08:00 (6)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 44 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021090; Age (Nervous system disorders/ Tension headache/ WORSENING OF TENSION HEADACHE	•	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021166; Age (Musculoskeletal and connective tissue disorders/ Muscle spasms/ MUSCLE SPASM (BACK)	(Years): 28; Gender: F; 2020-06-22 (18)/ 2020-06-26 (22)		THER: 3	ASHKENAZI No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Tension headache/ TENSION HEADACHE	2020-07-31 (25)/ 2020-08-02 (27)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 45 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021166; Age (Y Injury, poisoning and procedural complications/ Breast injury/ RIGHT BREAST INJURY	2020-11-29 (146)/	Race: O' Yes/ Yes/ No	THER: 3	ASHKENAZI No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Psychiatric disorders/ Anxiety/ WORSENING OF ANXIETY	2021-01-20 (198)/ 2021-02-10 (219)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Psychiatric disorders/ Insomnia/ WORSENING OF INSOMNIA	2021-01-20 (198)/ 2021-02-10 (219)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Psychiatric disorders/ Major depression/ WORSENING OF MAJOR DEPRESSIVE DISORDER	2021-01-20 (198)/ 2021-02-10 (219)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 46 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021167; Age (Ye	ears): 23; Gender: F;	Race: W	HITE				
Blood and lymphatic system	2021-01-04 (182)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
disorders/	2021-01-11 (189)	Yes/				CHANGED/	RESOLVED
Lymphadenopathy/		No				NONE	
LEFT ANTERIOR CERVICAL CHAIN	1						
LYMPH NODE							
Subject ID: US2021179; Age (Ye	ears): 38; Gender: F;	Race: W	HITE				
Neoplasms benign,	2020-06-11 (4)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
malignant and unspecified	2020-07-03 (26)	No/				CHANGED/	RESOLVED
(incl cysts and polyps)/		No				NONE	
Benign neoplasm of skin/							
BENIGN SKIN LESION RIGHT							
THIGH							
Skin and subcutaneous	2020-09-19 (75)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
tissue disorders/	2020-11-01 (118)	Yes/	_		,	CHANGED/	RESOLVED
Acne/	, ,	No				CONCOMITANT	
ACNE BUTTOCKS						MEDICATION	
		INO					

Notes listed on the last page.

Page 47 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021179; Age (Y Gastrointestinal disorders/ Abdominal pain/ ABDOMINAL PAIN	•	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-10-04 (90)/ 2020-10-07 (93)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031004; Age (Y Nervous system disorders/ Syncope/ SYNCOPAL EPISODE		Race: W. Yes/ No/ No	HITE 1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Axillary pain/ BILATERAL AXILLARY TENDERNESS	2020-06-29 18:00 (1) 2020-07-07 10:00 (9)	/Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 48 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031004; Age (Y Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	ears): 31; Gender: F; 2020-07-12 (14)/ 2020-07-22 (24)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031011; Age (Y Nervous system disorders/ Headache/ HEADACHE			HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2031016; Age (Y Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	•	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 49 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031042; Age (Y Nervous system disorders/ Headache/ HEADACHE	•	/Yes/	HITE 2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-07 13:27 (1), 2020-07-17 22:56 (12)		1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031056; Age (YInfections and infestations/Infected bite/LEFT KNEE INFECTION FROM BUBITE	2020-08-26 (58)/ 2020-09-07 (70)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 50 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2031057; Age (Y	Years): 26; Gender: M;	Race: W	HITE				
Respiratory, thoracic and mediastinal disorders/Cough/COUGH	2020-07-30 (30)/ 2020-08-01 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Nasal congestion/ NASAL CONGESTION	2020-07-30 (30)/ 2020-08-01 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-30 (30)/ 2020-08-01 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 51 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2031066; Age (Ye	ears): 40; Gender: F;	Race: W	HITE				
Nervous system disorders/	2020-11-13 (137)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
Headache/	2020-12-01 (155)	No/				NONE	RESOLVED
HEADACHE		No					
Nervous system disorders/	2020-11-13 (137)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
Lethargy/	2020-12-01 (155)	No/				NONE	RESOLVED
LETHARGY		No					
Musculoskeletal and	2020-11-13 (137)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
connective tissue	2020-12-01 (155)	No/				NONE	RESOLVED
disorders/		No					
Musculoskeletal chest pain/							
CHEST TIGHTNESS-NON CARDIAC							
MUSCULOSKELETAL							

Notes listed on the last page.

Page 52 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031072; Age (Y Injury, poisoning and procedural complications/ Foreign body in eye/ RIGHT EYE IRRITATION SECONDARY TO FOREIGN OBJECT IN EYE	2020-06-17 (15)/	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-11-17 (135)/ 2020-11-22 (140)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Vascular disorders/ Hypertension/ HYPERTENSION	2021-01-25 (204)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 53 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041007; Age (Y Pregnancy, puerperium and perinatal conditions/ Abortion spontaneous/ SPONTANEOUS ABORTION		Race: W Yes/ Yes/ No	HITE 1	Yes/	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041016; Age (Y Infections and infestations/ Viral infection/ VIRAL SYNDROME OF UNKNOWN ETIOLOGY	Tears): 39; Gender: M; 2020-12-09 (149)/ 2021-01-21 (192)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NA	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2041023; Age (Y Infections and infestations/ Viral infection/ VIRAL SYNDROME OF UNKNOWN ETIOLOGY	<pre>Years): 53; Gender: F; 2020-09-24 (88)/ 2020-10-02 (96)</pre>	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 54 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

	Start Date and	TEAE/ MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.		-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2041027; Age (Ye	ears): 40; Gender: F;	Race: W	HITE				
Respiratory, thoracic and mediastinal disorders/Cough/COUGH	2020-09-27 (91)/ 2020-11-03 (128)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Vomiting/ VOMITING	2020-09-27 (91)/ 2020-11-03 (128)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Chest discomfort/ CHEST TIGHTNESS/PRESSURE	2020-09-27 (91)/ 2020-11-03 (128)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 55 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041027; Age (Y Infections and infestations/ Viral infection/ VIRAL SYNDROME OF UNKNOWN ETIOLOGY	ears): 40; Gender: F; 2020-12-05 (160)/ 2020-12-11 (166)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041047; Age (Y Infections and infestations/ COVID-19/ COVID-19 INFECTION	ears): 33; Gender: M; 2020-08-04 (36)/ 2020-08-13 (45)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041049; Age (Y Nervous system disorders/ Tremor/ BILATERAL LEG TREMORS	•		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 56 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041051; Age (Metabolism and nutrition disorders/ Vitamin B12 deficiency/ VITAMIN B12 DEFICIENCY	Years): 25; Gender: F; 2020-10-16 (109)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041076; Age (General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-02 17:00 (1)	/ Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-06-03 (2)/ 2020-06-12 (11)	Yes/ No/ Yes	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 57 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (Yes) General disorders and administration site conditions/ Fatigue/ FATIGUE DUE TO SEASONAL ALLERGIES	<pre>/ears): 40; Gender: F; 2020-07-06 (1)/ 2020-07-25 (20)</pre>	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MYALGIA LEFT ARM	2020-07-06 13:30 (1) 2020-07-14 13:30 (9)	/Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-06 13:30 (1) 2020-07-15 (10)	/Yes/ No/ Yes	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 58 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (Y Nervous system disorders/ Headache/ HEADACHE	Years): 40; Gender: F; 2020-08-10 (36)/ 2020-08-13 (39)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-08-10 (36)/ 2020-08-13 (39)	Yes/ No/ No	1	No	NR/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Chest discomfort/ CHEST TIGHTNESS-UNKNOWN ORIGIN	2020-08-10 (36)/ 2020-08-13 (39)	Yes/ No/ No	1	No	NR/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 59 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (Ye Infections and infestations/ Eye infection/ BILATERAL EYE INFECTION	ears): 40; Gender: F; 2020-10-19 (106)/ 2020-11-16 (134)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041077; Age (Your Nervous system disorders/ Paraesthesia/ BILATERAL NUMBNESS/TINGLING IN HANDS	2020-07-05 (5)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE	2020-07-14 (14)/ ONGOING	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 60 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041092; Age (Your Vascular disorders/ Hypertension/ HYPERTENSION	<pre>Tears): 52; Gender: F; 2020-06-24 (17)/ ONGOING</pre>	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051009; Age (Yes Musculoskeletal and connective tissue disorders/Back pain/MUSCULOSKELETAL BACK PAIN	Years): 51; Gender: M; 2020-06-19 (18)/ 2020-07-24 (53)	Race: WH Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051010; Age (Y Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	Years): 42; Gender: F; 2020-06-14 (13)/ 2020-08-03 (63)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 61 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051011; Age (Y Injury, poisoning and procedural complications/ Epicondylitis/ TENNIS ELBOW BILATERAL	2020-08-21 (46)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051018; Age (Y Injury, poisoning and procedural complications/ Corneal abrasion/ LEFT CORNEAL ABRASION	2020-10-13 (99)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051032; Age (Y Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RUNNY NOSE (UNKNOWN ETIOLOGY)	•		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 62 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051033; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS	ears): 40; Gender: F; 2020-07-07 (1)/ 2020-07-15 (9)	Race: W Yes/ No/ Yes	HITE 3	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-07 (1)/ 2020-07-15 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-09 (3)/ 2020-07-10 (4)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 63 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051034; Age (Y Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-06-09 (7)/ 2020-06-15 (13)	Race: W. Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051040; Age (Y Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS (THIGHS, TRUNK, FOREARMS, ANKLES)	2020-06-20 (16)/ 2020-06-27 (23)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 64 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051042; Age (Ye Gastrointestinal disorders/Toothache/TOOTHACHE	· · · · · · · · · · · · · · · · · · ·	Race: W Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Infections and infestations/ Urethritis/ URETHRITIS	2020-08-16 (47)/ 2020-08-21 (52)	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Staphylococcus test positive/ STAPH POSITIVE URINALYSIS	2020-09-16 (78)/ 2020-09-30 (92)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 65 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051043; Age (Young) Nervous system disorders/ Headache/ HEADACHE	ears): 38; Gender: F; 2020-10-16 (108)/ 2020-10-16 (108)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2061001; Age (Your Infections and infestations/ Nasopharyngitis/ COMMON COLD	ears): 38; Gender: F; 2020-07-18 (9)/ 2020-08-01 (23)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Gastritis/ GASTRITIS	2020-12-24 (168)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2061006; Age (Yanfections and infestations/ Herpes zoster/ SHINGLES	ears): 35; Gender: F; 2021-01-18 (202)/ 2021-01-25 (209)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 66 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061009; Age (Y Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-10-05 (91)/ 2020-10-10 (96)	Race: W Yes/ Yes/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061019; Age (Y Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	· · · · · · · · · · · · · · · · · · ·	Race: W Yes/ Yes/ No	HITE 2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061026; Age (Y Respiratory, thoracic and mediastinal disorders/ Nasal congestion/ NASAL CONGESTION	2020-09-14 (70)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 67 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061026; Age (Ye Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	ears): 43; Gender: M; 2020-09-15 (71)/ 2020-09-18 (74)		HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2071001; Age (Yet Psychiatric disorders/Anxiety/ANXIETY		Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Infections and infestations/ Sinusitis/ SINUS INFECTION	2020-09-11 (74)/ 2020-09-15 (78)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 68 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2071001; Age Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATIORY INFECTION	(Years): 28; Gender: F; 2020-12-26 (180)/ 2021-01-19 (204)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071004; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 39; Gender: M; 2020-07-09 (2)/ 2020-07-16 (9)	Race: W Yes/ Yes/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-09 08:00 (1) 2020-07-16 (9)	/Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 69 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	- '	
Preferred Term/	End Date and	cited	Sev.		-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071004; Age (Years): 39; Gender: M;	Race: W	HITE				
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-14 (7)/ 2020-07-15 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATORY INFECTION	2020-10-14 (99)/ 2020-10-16 (101)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071030; Age (General disorders and administration site conditions/ Injection site erythema/ REDNESS AT INJECTION SITE	Years): 37; Gender: F; 2020-06-12 (10)/ 2020-06-18 (16)	Race: W Yes/ No/ No	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 70 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071030; Age (Y General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	Years): 37; Gender: F; 2020-06-12 (10)/ 2020-06-18 (16)	Race: W Yes/ No/ No	HITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site induration/ ENDURATION AT INJECTION SIT	2020-06-12 (10)/ 2020-07-18 (46)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Tinea pedis/ WORSENING OF TINEA PEDIS LEFT BIG TOE	2020-09-27 (84)/ 2020-12-31 (179)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 71 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

	Obsert Pate and	TEAE/				Table Balance	
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071074; Age (Y Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATORY INFECTION	Tears): 40; Gender: F; 2020-12-06 (151)/ 2020-12-23 (168)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081036; Age (Y Nervous system disorders/ Migraine/ WORSENING OF MIGRAINES		Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-12-15 (160)/ 2020-12-25 (170)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 72 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	_	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081041; Age (Y	ears): 41; Gender: M;	Race: W	HITE				
Respiratory, thoracic and mediastinal disorders/ Nasal congestion/ NASAL CONGESTION	2020-12-14 (161)/ 2020-12-28 (175)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081052; Age (Y General disorders and administration site conditions/ Injection site pain/ LEFT TRAPEZIUS REGION, TRANSIENT LOCAL MUSCLE PAIN RELATED TO INJECTION	ears): 37; Gender: M; 2020-06-05 12:03 (1), 2020-06-05 12:18 (1)		HITE 1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/Concussion/MILD CONCUSSION	2020-10-12 (96)/ 2020-10-19 (103)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 73 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

			TEAE/					
	Start Date and		MAAE/				Action Taken	
System Organ Class/	Time (Relative Da	ιу) /	Soli-		SAE/	Relation-	- '	
Preferred Term/	End Date and		cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Da	ıy)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081052; Age (Y	ears): 37; Gender:	M;]	Race: W	HITE				
Injury, poisoning and	2020-10-12 (96)/		Yes/	2	No	NR/NR	DOSE NOT	RECOVERED/
procedural complications/	2020-10-23 (107)		Yes/				CHANGED/	RESOLVED
Muscle strain/			No				CONCOMITANT	
NECK STRAIN (CAR ACCIDENT)							MEDICATION	
Respiratory, thoracic and	2020-10-21 (105)/	′	Yes/	2	No	NR/NR	DOSE NOT	RECOVERING/
mediastinal disorders/	ONGOING		No/				CHANGED/	RESOLVING
Oropharyngeal pain/			No				CONCOMITANT	
SORE THROAT							MEDICATION	
General disorders and	2020-10-27 (111)/	,	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
administration site	2020-11-16 (131)		Yes/				NONE	RESOLVED
conditions/			No					
Fatique/								
FATIGUE								

Notes listed on the last page.

Page 74 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081059; Age Immune system disorders/ Seasonal allergy/ RUNNY NOSE (SEASONAL ALLERGIES)				No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Immune system disorders/ Seasonal allergy/ SORE THROAT (SEASONAL ALLERGIES)	2020-08-05 (24)/ 2020-08-09 (28)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Neck pain/ NECK PAIN	2021-02-21 (224)/ 2021-02-28 (231)	Yes/ No/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 75 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011089; Age (Note of the second seco	•	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Pregnancy, puerperium and perinatal conditions/ Abortion missed/ MISCARRIAGE (MISSED ABORTION)	2021-02-26 (232)/ 2021-03-10 (244)	Yes/ Yes/ No	2	Yes/	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021063; Age (Yange Infections and infestations/ Acute sinusitis/ ACUTE SINUSITIS	Years): 40; Gender: F; 2021-01-26 (204)/ 2021-02-02 (211)	Race: Wi Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 76 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day), End Date and Time (Relative Day)	TEAE/ MAAE/ 'Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021074; Age (Y General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	ears): 28; Gender: F; 2020-06-02 18:00 (1) 2020-06-17 08:00 (15	/ Yes/	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021080; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 49; Gender: F; 2020-06-05 21:35 (1) 2020-06-18 08:32 (13	/ Yes/	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Dry mouth/ DRY MOUTH	2020-07-09 08:00 (1) 2020-07-13 00:13 (5)		1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 77 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021080; Age (Y Gastrointestinal disorders/ Abdominal discomfort/ GASTROINTESTINAL DISTRESS (NOS)	· · · · · · · · · · · · · · · · · · ·		HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021099; Age (Y Musculoskeletal and connective tissue disorders/ Axillary mass/ LUMP RIGHT AXILLARY REGION IPSILATERAL-SAME SIDE OF VACCINATION SITE	ears): 49; Gender: F; 2020-07-17 (18)/ 2020-07-17 (18)	Race: W Yes/ No/ No	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 78 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021101; Age (General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	Years): 35; Gender: F; 2020-06-20 (13)/ 2020-06-20 (13)	Race: W Yes/ No/ No	HITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021151; Age (General disorders and administration site conditions/ Mass/ LEFT POSTERIOR HEAD LUMP	Years): 30; Gender: F; 2020-07-05 (28)/ 2020-07-08 (31)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/Rhinorrhoea/RUNNY NOSE	2020-07-10 03:15 (1) 2020-07-10 08:00 (1)	/Yes/ No/ No	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 79 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

			TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date Time (Relat End Date an Time (Relat	ive Day)/	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021151; Age (Ye Nervous system disorders/Migraine/MIGRAINE		ender: F; (101)/	Race: W. Yes/ Yes/ No		No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA		, , ,	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Vomiting/ VOMITING	2020-10-17 2020-10-19	, ,	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Neck pain/ NECK PAIN	2020-10-17 2020-10-19	(101) / (103)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 80 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date Time (Relat End Date an Time (Relat	ive Day)/	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021151; Age (Y General disorders and administration site conditions/ Chills/ CHILLS	ears): 30; G 2020-10-17 2020-10-19	(101)/	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pyrexia/ FEVER	2020-10-18 2020-10-20	, ,	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-10-18 2020-10-23		Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 81 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021154; Age (Y	ears): 34; Gender: F;	Race: W	HITE				
Injury, poisoning and	2020-06-24 (20)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
procedural complications/	2020-06-28 (24)	No/				CHANGED/	RESOLVED
Arthropod bite/		No				CONCOMITANT	
BUG BITE (BOTH ARMS)						MEDICATION	
Nervous system disorders/	2020-07-08 20:56 (1)	/ Yes/	3	No	R/R	DOSE NOT	RECOVERED/
Headache/	2020-07-16 12:00 (8)	No/				CHANGED/	RESOLVED
HEADACHE		Yes				CONCOMITANT	
						MEDICATION	
Skin and subcutaneous	2020-12-15 (161)/	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
tissue disorders/	2020-12-21 (167)	Yes/				CONCOMITANT	RESOLVED
Dermatitis contact/		No				MEDICATION	
CONTACT DERMATITIS RIGHT							
HAND							

Notes listed on the last page.

Page 82 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021164; Age (Skin and subcutaneous tissue disorders/ Acne/ WORSENING OF ACNE AROUND MOUTH	Years): 34; Gender: F; 2020-06-10 (3)/ 2020-07-01 (24)	Race: W Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Axillary pain/ UNDERARM TENDERNESS	2020-06-14 (7)/ 2020-06-18 (11)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021180; Age (General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-14 (7)/ 2020-07-01 (24)	Race: W Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 83 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021180; Age (Y General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE	ears): 31; Gender: M; 2020-07-08 21:00 (1), 2020-07-17 09:00 (9)		HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-07-08 21:00 (1), 2020-07-17 09:00 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Muscle contusion/ BRUISING RIGHT POSTERIOR HAMSTRING UNKNOWN	2020-07-14 (7)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 84 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/	Start Date and Time (Relative Day)/ End Date and	cited	Sev.	SAE/ Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021180; Age (Yangury, poisoning and procedural complications/Muscle strain/BACK STRAIN	2020-07-29 (22)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031013; Age (Your Injury, poisoning and procedural complications/Meniscus injury/TORN MENISCUS RIGHT KNEE	2020-08-10 (42)/	Race: W. Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2031035; Age (Your Nervous system disorders/ Headache/ HEADACHE		Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 85 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031035; Age (Year Respiratory, thoracic and mediastinal disorders/Rhinorrhoea/RHINORRHEA	ears): 48; Gender: F; 2020-07-27 (29)/ 2020-08-03 (36)	Race: WI Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-09-11 (75)/ 2020-09-24 (88)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-11-13 (138)/ 2020-11-20 (145)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 86 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031050; Age Infections and infestations/ Influenza/ INFLUENZA A	(Years): 51; Gender: F; 2021-02-21 (236)/ 2021-03-01 (244)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031079; Age Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	(Years): 34; Gender: F; 2020-07-30 (29)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Gastrointestinal disorders Intestinal obstruction/ INTESTINAL OBSTRUCTION	s/ 2020-11-13 (135)/ 2020-11-13 (135)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 87 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041008; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 37; Gender: M; 2020-07-02 (2)/ 2020-07-10 (10)	Race: W Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041046; Age Infections and infestations/ Otitis media/ LEFT OTITIS MEDIA	(Years): 23; Gender: M; 2020-10-14 (105)/ 2020-10-25 (116)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Bronchitis/ BRONCHITIS	2020-11-06 (128)/ 2020-11-15 (137)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 88 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041046; Age (Yes) Psychiatric disorders/ Depression/ WORSENING DEPRESSION	Years): 23; Gender: M; 2020-12-02 (154)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Musculoskeletal and connective tissue disorders/ Muscle spasms/ LOW BACK SPASMS	2021-02-03 (217)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041048; Age (Y Infections and infestations/ Viral infection/ VIRAL SYNDROME OF UNKNOWN ETIOLOY	Years): 25; Gender: F; 2021-01-25 (209)/ 2021-01-29 (213)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 89 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041060; Age (Y General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE	ears): 19; Gender: F; 2020-06-03 (2)/ 2020-06-09 (8)		HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-03 (2)/ 2020-06-09 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041061; Age (Y Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	ears): 52; Gender: F; 2020-07-06 (1)/ 2020-07-16 (11)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 90 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041073; Age (General disorders and administration site conditions/ Fatigue/ FATIGUE	Years): 44; Gender: F; 2020-06-03 09:38 (1), 2020-06-12 12:38 (10)	Yes/	HITE 1	No	R/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-03 (4)/ 2020-07-11 (12)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041080; Age (Infections and infestations/ COVID-19/ COVID-19 INFECTION	Years): 26; Gender: F; 2021-01-02 (186)/ 2021-01-06 (190)	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 91 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051012; Age (Y Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS LEFT ARM	2020-06-03 (2)/ 2020-06-05 00:00 (3)	Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051045; Age (Y Vascular disorders/ Diastolic hypertension/ DIASTOLIC HYPERTENSION	2020-07-16 (9)/		HITE 3	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2061008; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES, GENERALIZED	Tears): 31; Gender: M; 2020-07-06 20:00 (1); 2020-07-29 20:00 (24)	/ Yes/	HITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 92 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061008; Age (Young Musculoskeletal and connective tissue disorders/Myalgia/MUSCLE ACHES, GENERALIZED	Years): 31; Gender: M; 2020-07-12 06:00 (6), 2020-07-14 07:00 (8)	/ Yes/	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061020; Age (No Neoplasms benign, malignant and unspecified (incl cysts and polyps)/ Basal cell carcinoma/ BASAL CELL CARCINOMA	2021-01-20 (198)/		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061023; Age (Yellow) General disorders and administration site conditions/ Axillary pain/ UNDERARM PAIN - LEFT ARM	<pre>Zears): 19; Gender: F; 2020-06-10 (6)/ 2020-06-12 (8)</pre>		LACK O	R AFRICAN No	AMERICAN R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 93 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061023; Age (Y Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES, GENERALIZED	ears): 19; Gender: F; 2020-07-12 (7)/ 2020-07-18 (13)		LACK O	R AFRICAN No	AMERICAN R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ DEPRESSION	2020-11-05 (123)/ 2021-01-20 (199)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071002; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS ALL OVER BODY	ears): 39; Gender: F; 2020-07-01 08:00 (1), 2020-07-08 08:00 (8)		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 94 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071002; Age (Your Nervous system disorders/ Headache/ HEADACHE		/ Yes/	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-02 (3)/ 2020-08-02 (34)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-07-04 (5)/ 2020-07-09 (10)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 95 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/	Start Date and Time (Relative Day)/ End Date and	TEAE/ MAAE/ Soli- cited	Sev.	SAE/ Criteria	Relation- ship to	Action Taken with IP/ Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071036; Age (*Psychiatric disorders/Anxiety/ANXIETY	Years): 18; Gender: M; 2020-08-01 (20)/ ONGOING	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071039; Age (General disorders and administration site conditions/ Injection site pain/ MILD PAIN AT INJECTION SITE	2020-06-15 (11)/ 2020-06-16 (12)	Race: W Yes/ No/ No	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site erythema/ ERYTHEMA TO INJECTION SITE	2020-06-15 (11)/ 2020-06-17 (13)	Yes/ No/ No	2	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 96 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071073; Age (Y General disorders and administration site conditions/ Injection site erythema/ REDNESS AT INJECTION SITE	Tears): 26; Gender: F; 2020-06-18 (11)/ 2020-06-20 (13)	Race: B Yes/ No/ No	LACK C	R AFRICAN No	AMERICAN R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-18 (11)/ 2020-06-20 (13)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081025; Age (Y Gastrointestinal disorders/ Haemorrhoids/ HEMORRHOIDS		Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 97 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081025; Age (Ye Injury, poisoning and procedural complications/Limb injury/INJURY OF RIGHT PINKY FINGER	2020-09-22 (78)/ 2020-12-28 (175)	Race: WH Yes/ Yes/ No	IITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinitis allergic/ ALLERGIC RHINITIS	2021-02-19 (228)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Eye disorders/ Conjunctivitis allergic/ ALLERGIC CONJUNCTIVITIS	2021-03-10 (247)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 98 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081028; Age (Musculoskeletal and connective tissue disorders/ Muscle spasms/ MUSCLE SPASM [LOWER BACK]	Years): 51; Gender: M; 2020-06-16 (15)/ 2020-07-07 (36)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081045; Age (Skin and subcutaneous tissue disorders/ Skin discolouration/ WHITE FINGERTIPS	Years): 43; Gender: M; 2020-06-28 (25)/ 2020-06-28 (25)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Paraesthesia/ FEELING OF "PINS AND NEEDLES" IN EXTREMITIES [CAUSALITY, INVESTIGATIONAL PRODUCT]	2020-07-08 22:00 (2) 2020-07-15 07:00 (8)		1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 99 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081045; Age (Y Gastrointestinal disorders/Paraesthesia oral/FEELING OF "PINS AND NEEDLES" IN TONGUE [CAUSALITY, INVESTIGATIONAL PROTOCOL]	•		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Abdominal discomfort/ STOMACH PRESSURE	2020-07-12 (6)/ 2020-07-14 (8)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081063; Age (Y Psychiatric disorders/ Depression/ DEPRESSION		Race: W Yes/ No/ No	HITE 3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 100 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081063; Age Psychiatric disorders/ Anxiety/ ANXIETY	(Years): 22; Gender: M; 2020-10-12 (97)/ ONGOING	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081064; Age Infections and infestations/ Gastroenteritis/ ACUTE GASTROENTERITIS	(Years): 48; Gender: M; 2020-07-09 (1)/ 2020-07-10 (2)	Race: W Yes/ Yes/ No	HITE 2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 101 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) / End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria	-	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011007; Age (General disorders and administration site conditions/ Injection site erythema/ REDNESS AT INJECTION SITE				No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011116; Age (Injury, poisoning and procedural complications/ Nail avulsion/ LEFT TOENAIL AVULSED	2020-08-20 (25)/	Race: W Yes/ No/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011124; Age (Infections and infestations/ Herpes simplex/ HERPES SIMPLEX II	Years): 60; Gender: F; 2020-09-17 (56)/ 2020-10-01 (70)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 102 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	- '	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
<u>Verbatim</u>	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011131; Age (Y	ears): 57; Gender: F;	Race: W	HITE				
Investigations/	2020-09-10 (49)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	NOT RECOVERED/
Blood triglycerides	ONGOING	Yes/				NONE	NOT RESOLVED
increased/		No					
HIGH TRIGLYCERIDES							
Skin and subcutaneous	2020-11-15 (115)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	NOT RECOVERED/
tissue disorders/	ONGOING	Yes/				CONCOMITANT	NOT RESOLVED
Hirsutism/		No				MEDICATION	
HIRSUTISM (UNWANTED HAIR							
GROWTH ON FACE)							
Subject ID: US2011142; Age (Y	ears): 64: Gender: M:	Race: W	HITE				
Gastrointestinal disorders/		Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
Dental caries/	2021-01-26 (184)	Yes/			•	CONCOMITANT	RESOLVED
TOOTH EXTRACTION DENTAL	,	No				MEDICATION	
CARIES							

Notes listed on the last page.

Page 103 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.		-	Other Action	
<u>Verbatim</u>	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011152; Age (Yes General disorders and administration site conditions/ Injection site bruising/ LEFT UPPER ARM BRUISING @ THE INJECTION SITE	Years): 66; Gender: F; 2020-07-28 (2)/ 2020-09-02 (38)	Race: W Yes/ No/ No	HITE 1	No	NR/R	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2011156; Age (Y Investigations/ Blood cholesterol increased WORSENING OF HIGH CHOLESTEROL	2020-11-03 (99)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2021021; Age (Yellow Musculoskeletal and connective tissue disorders/Plantar fasciitis/PLANAR FACSCITIS	Years): 71; Gender: M; 2020-08-25 (61)/ 2020-08-31 (67)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 104 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021022; Age (Ye Injury, poisoning and procedural complications/ Tooth fracture/ BROKEN TOOTH	2020-07-19 (14)/	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021043; Age (Yes) Skin and subcutaneous tissue disorders/ Dermatitis contact/ POISON IVY ALLERGIC CONTACT DERMATITIS - BILATERAL LEGS	ears): 65; Gender: M; 2020-06-10 (10)/ 2020-06-17 (17)	Race: Wi Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Immune system disorders/ Allergy to arthropod sting/ ALLERGIC REACTION WASP BITE		Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 105 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	- '	
Preferred Term/	End Date and	cited	Sev.		-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021130; Age ()	<pre>Years): 80; Gender: F;</pre>	Race: W	HITE				
Investigations/ Blood pressure increased/ POST DOSE ELEVATED BLOOD PRESSURE	2020-06-26 12:10 (1) 2020-07-06 12:10 (11		3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Rash/ RASH RIGHT WRIST	2020-08-25 (28)/ 2020-08-27 (30)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RHINORRHEA	2020-11-11 (106)/ 2020-11-11 (106)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 106 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	-	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021185; Age (Y Reproductive system and breast disorders/ Postmenopausal haemorrhage/ POSTMENOPAUSAL BLEEDING	ears): 55; Gender: F; 2020-07-04 (9)/ 2020-07-11 (16)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	2020-08-31 (32)/ 2020-08-31 (32)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED WITH SEQUELAE/ DUE TO SUBJECT BEING DIAGNOSIS IN 2000 BUT WAS NOT PRESCRIBED ANY MEDICATION. THIS WILL CONTINUE TO BE APART OF SUBJECT'S MEDICAL HISTORY
Infections and infestations/ COVID-19/ POSITIVE COVID-19 ILLNESS	2021-01-27 (181)/ 2021-02-12 (197)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 107 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021196; Age Gastrointestinal disorders Large intestine polyp/ 2 POLYPS COLON BENIGN		Race: WH Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021206; Age Musculoskeletal and connective tissue disorders/ Exostosis/ BONE SPUR 2ND RIGHT TOE	(Years): 64; Gender: F; 2020-07-08 (7)/ 2020-07-30 (29)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Bursitis/ BURSITIS RIGHT HIP	2020-07-13 (12)/ 2020-07-16 (15)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 108 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021206; Age (Y Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	ears): 64; Gender: F; 2020-10-05 (63)/ 2020-10-06 (64)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021222; Age (Y Injury, poisoning and procedural complications/ Arthropod bite/ FIRE ANT BITES EXTREMITIES	2020-08-22 (23)/	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Eye infection/ RIGHT EYE INFECTION	2020-12-23 (146)/ 2020-12-29 (152)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 109 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031089; Age Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ LEFT SHOULDER PAIN	(Years): 65; Gender: M; 2020-08-13 (16)/ 2020-08-20 (23)	Race: WHITE Yes/ 1 No/ No	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031102; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 57; Gender: F; 2020-08-28 (26)/ 2020-08-28 (26)	Race: WHITE Yes/ 1 No/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031103; Age Respiratory, thoracic and mediastinal disorders/ Sinus congestion/ SINUS CONGESTION		Race: WHITE Yes/ 1 No/ No	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 110 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited S	SAE/ Sev. Criter: [1] [2]	Relation- a ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031116; Age Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-10-11 (74)/ 2020-10-18 (81)	Race: WHI Yes/ 1 No/ No	TE 1 No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031129; Age Infections and infestations/ Sinusitis/ SINUSITIS	(Years): 61; Gender: M; 2020-08-23 (25)/ 2020-08-27 (29)	Race: WHI Yes/ 1 Yes/ No	TE 1 No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041114; Age Musculoskeletal and connective tissue disorders/ Back pain/ THORACIC BACK PAIN	(Years): 62; Gender: M; 2021-02-13 (195)/ 2021-02-19 (201)	Race: WHI Yes/ 1 Yes/ No	TE 1 No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 111 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2041142; Age (Y	ears): 63; Gender: M;	Race: W	HITE				
Metabolism and nutrition	2021-01-27 (181)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
disorders/	2021-02-15 (200)	Yes/				CONCOMITANT	RESOLVED
Hypercholesterolaemia/		No				MEDICATION	
HYPERCHOLESTEROLEMIA							
Subject ID: US2041146; Age (Y	ears): 59; Gender: F;	Race: W	HITE				
Infections and	2020-07-05 (4)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2020-07-10 (9)	Yes/				CHANGED/	RESOLVED
Cellulitis/		No				CONCOMITANT	
CELLULITIS- RIGHT FOREARM						MEDICATION	
Blood and lymphatic system	2020-07-31 (1)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERING/
disorders/	ONGOING	No/				CHANGED/	RESOLVING
Leukopenia/		No				NONE	
LEUKOPENIA							

Notes listed on the last page.

Page 112 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051063; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 56; Gender: M; 2020-12-10 (136)/ ONGOING	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2051072; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 69; Gender: M; 2020-08-24 (22)/ 2020-09-21 (50)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051112; Age Gastrointestinal disorder Abdominal tenderness/ ABDOMINAL TENDERNESS (ETIOLOGY UNKNOWN)		Race: Wi Yes/ No/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 113 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2051112; Age	(Years): 60; Gender: F;	Race: W	HITE				
Infections and	2020-10-01 (60)/	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
infestations/	2020-10-16 (75)	Yes/				CONCOMITANT	RESOLVED
Gastroenteritis/		No				MEDICATION	
GASTROENTERITIS'							
Subject ID: US2061035; Age	(Years): 71; Gender: M;	Race: W	HITE				
Investigations/	2020-06-26 13:41 (1)	/Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
Heart rate decreased/	2020-06-26 19:00 (1)	No/				CHANGED/	RESOLVED
DECREASED HEART RATE		No				NONE	
Infections and	2020-12-31 (165)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2021-01-17 (182)	Yes/				CHANGED/	RESOLVED
COVID-19/		No				NONE	
COVID-19 INFECTION							

Notes listed on the last page.

Page 114 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061043; Age Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES - GENERALIZED	(Years): 59; Gender: F; 2020-07-28 11:00 (1), 2020-08-03 18:00 (8)		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES	2020-07-28 11:00 (1), 2020-08-03 18:00 (8)	/Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-28 11:00 (1), 2020-08-03 18:00 (8)	/Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 115 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev AR [1]	SAE/ . Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061046; Age Infections and infestations/ Asymptomatic COVID-19/ ASYMPTOMATIC COVID-19	(Years): 62; Gender: F; 2020-12-15 (142)/ 2020-12-15 (142)	Race: WHITE Yes/ 1 Yes/ No	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071005; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 56; Gender: F; 2020-11-22 (140)/ 2020-12-06 (154)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071041; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 64; Gender: M; 2020-09-27 (88)/ 2020-10-12 (103)	Race: WHITE Yes/ 3 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 116 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071085; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ ARTHRALGIA KNEE JOINT PAIN	ears): 75; Gender: F; 2020-06-29 (4)/ 2020-07-06 (11)	Race: WH Yes/ No/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Investigations/ Cardiac murmur/ SYSTOLIC MURMUR 2/4	2020-08-24 (28)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071086; Age (Y Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATORY INFECTION	ears): 68; Gender: M; 2020-11-09 (104)/ 2020-11-16 (111)	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 117 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2071088; Age (Gastrointestinal disorders Gastrooesophageal reflux disease/ ACID REFLUX	•	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071092; Age (Infections and infestations/ COVID-19/ COVID 19 INFECTION	Years): 61; Gender: F; 2020-11-20 (123)/ 2020-11-30 (133)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Pneumonia/ PNEUMONIA	2020-11-24 (127)/ 2020-11-30 (133)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 118 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071100; Age (Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS	Years): 61; Gender: M; 2020-08-09 (6)/ 2020-08-12 (9)	Race: W Yes/ No/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Metabolism and nutrition disorders/ Hyperlipidaemia/ HYPERLIPIDEMIA	2020-08-24 (21)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Psychiatric disorders/ Anxiety/ ANXIETY	2021-01-08 (158)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 119 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071100; Age (Y Reproductive system and breast disorders/ Prostatomegaly/ ENLARGED PROSTATE	ears): 61; Gender: M; 2021-01-08 (158)/ ONGOING	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071102; Age (Y Nervous system disorders/ Restless legs syndrome/ WORSENING OF RESTLESS LEG SYNDROME	•		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071103; Age (Y Gastrointestinal disorders/ Duodenitis/ DUODENITIS		Race: WI Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 120 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081004; Age (Renal and urinary disorders/ Haematuria/ HEMATURIA	Years): 60; Gender: F; 2020-06-09 (12)/ 2020-07-01 (34)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Back pain/ LOWER BACK PAIN	2020-06-26 (29)/ 2020-06-28 (31)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081005; Age (Skin and subcutaneous tissue disorders/ Angioedema/ SWOLLEN BLISTERED LIPS (INTERMITTENT ANGIOEDEMA)	Years): 55; Gender: F; 2020-06-09 (9)/ 2020-10-09 (131)	Race: Wi Yes/ Yes/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 121 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/	Start Date and Time (Relative Day)/	TEAE/ MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081007; Age (You Investigations/	ears): 64; Gender: F; 2020-06-01 10:05 (1);		HITE 1	No	NR/R	DOSE NOT	RECOVERED/
Blood pressure increased/ BLOOD PRESSURE ELEVATION	2020-06-01 20:00 (1)	No/ No				CHANGED/ NONE	RESOLVED
Respiratory, thoracic and mediastinal disorders/ Upper respiratory tract inflammation/ PI NOTED INFLAMMATION OF OROPHARNYX AT DAY 15 VISIT	2020-06-17 (17)/ 2020-06-30 (30)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081017; Age (Y-Respiratory, thoracic and mediastinal disorders/Oropharyngeal pain/SORE THROAT		Race: WH Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 122 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	-	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081029; Age (Y Investigations/ Computerised tomogram coronary artery abnormal/ CORONARY CALCIUM SCAN ABNORMAL (ELEVATED)	ears): 55; Gender: M; 2021-02-01 (210)/ ONGOING	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081066; Age (Y Nervous system disorders/ Headache/ HEADACHE	•	Race: W. Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081077; Age (Y Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	ears): 66; Gender: F; 2020-12-08 (128)/ 2020-12-19 (139)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 123 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081103; Age (Y Nervous system disorders/ Headache/ HEADACHE	ears): 58; Gender: M; 2020-07-18 (17)/ 2020-07-24 (23)	Race: War Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pyrexia/ FEVER	2020-07-18 (17)/ 2020-07-24 (23)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081125; Age (Y Infections and infestations/ Nasopharyngitis/ COMMON COLD	ears): 62; Gender: M; 2020-08-04 (2)/ 2020-08-10 (8)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 124 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011040; Age (Y General disorders and administration site conditions/ Chest pain/ CHEST PAIN, UNKNOWN DETAILS	2020-06-02 22:49 (2) 2020-06-02 23:35 (2)		LACK O 1	R AFRICAN No	AMERICAN NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Metabolism and nutrition disorders/ Insulin resistance/ INSULIN RESISTANCE	2020-11-13 (138)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Investigations/ Hormone level abnormal/ LOW HORMONE LEVELS	2020-11-13 (138)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 125 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011123; Age (Y Skin and subcutaneous tissue disorders/ Ecchymosis/ LEFT UPPER ARM ECCHYMOSIS, DUE TO INJURY	ears): 64; Gender: M; 2020-07-03 (8)/ 2020-08-09 (45)	Race: WH Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS	2020-07-30 (7)/ 2020-07-31 (8)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011125; Age (Y Gastrointestinal disorders/ Haemorrhoids/ HEMORRHOID	· · · · · · · · · · · · · · · · · · ·	Race: WI Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 126 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011127; Age (Y	ears): 63; Gender: M;	Race: W	HITE				
Injury, poisoning and procedural complications/ Heat exhaustion/ HEAT EXHAUSTION	2020-08-31 (39)/ 2020-11-15 (115)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Irritable bowel syndrome/ WORSENING OF IBS	2020-12-07 (137)/ 2021-02-15 (207)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2021-01 (162)/ ONGOING	Yes/ No/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 127 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011127; Age (Yet) Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT PAIN	ears): 63; Gender: M; 2021-02 (193)/ ONGOING	Race: W Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2011137; Age (Yes) Nervous system disorders/ Headache/ HEADACHE		Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-07-23 (28)/ 2020-07-23 (28)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 128 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	- '	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
<u>Verbatim</u>	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021004; Age (Note of the stations and infestations/Cellulitis/RIGHT FOOT CELLULITIS	Years): 72; Gender: F; 2020-12-26 (184)/ 2021-01-03 (192)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021012; Age (YEar and labyrinth disorders/Ear pain/OTALGIA	Years): 66; Gender: F; 2020-07-04 (6)/ 2020-07-15 (17)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021018; Age (Yange Infections and infestations/Pharyngitis/PHARYNGITIS	Years): 71; Gender: F; 2020-06-22 (25)/ 2020-06-30 (33)	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 129 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021018; Age (Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	Years): 71; Gender: F; 2020-07-01 (34)/ 2020-07-07 (40)	Race: Wi Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Back pain/ WORSENING OF BACK PAIN	2020-08-04 (23)/ 2020-11-26 (137)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021019; Age (Skin and subcutaneous tissue disorders/ Rash/ RASH ON RIGHT KNEE NON-URTICARIAL	Years): 59; Gender: M; 2020-06-01 (4)/ 2020-06-06 (9)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 130 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021019; Age (Y Renal and urinary disorders/ Nephrolithiasis/ NEPHROLITHIASIS (RIGHT)	ears): 59; Gender: M; 2020-06-24 (27)/ 2020-07-06 (39)	Race: Will Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinitis allergic/ ALLERGIC RHINITIS	2021-01-22 (205)/ 2021-02-01 (215)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021020; Age (Y Nervous system disorders/ Headache/ HEADACHE		Race: Wi Yes/ No/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 131 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-		
Preferred Term/	End Date and	cited	Sev.		-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021020; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 72; Gender: F; 2020-06-06 (6)/ 2020-06-16 (16)	Race: W. Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021045; Age (Y Gastrointestinal disorders/ Toothache/ TOOTHACHE	· · · · · · · · · · · · · · · · · · ·	Race: W. Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021205; Age (Y Skin and subcutaneous tissue disorders/ Pruritus/ GENERALIZED PRURITIS (UNKNOWN)	ears): 56; Gender: F; 2020-06-30 (5)/ 2020-07-16 (21)	Race: W. Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 132 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					_
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021205; Age (Y	ears): 56; Gender: F;	Race: W	HITE				
Skin and subcutaneous tissue disorders/ Pruritus/ GENERALIZED PURTITIS	2020-08-01 08:00 (1), 2020-08-05 17:00 (6)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Suspected COVID-19/ COVID-19 LIKE ILLNESS	2021-01-30 (184)/ 2021-02-10 (195)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021217; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 66; Gender: F; 2020-07-29 17:00 (1), 2020-08-05 16:23 (8)		HITE 3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 133 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021220; Age (Y Nervous system disorders/ Headache/ HEADACHE	•		LACK O	R AFRICAN No	AMERICAN NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Tendonitis/ LEFT POSTERIOR TIBIAL TENDONITIS	2021-02-16 (203)/ 2021-03-15 (230)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021226; Age (Y Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	· · · · · · · · · · · · · · · · · · ·		HITE 3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 134 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
System Organ Class/	Start Date and Time (Relative Day)/	MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021226; Age (Ye Infections and infestations/ Suspected COVID-19/ COVID LIKE ILLNESS	ears): 68; Gender: F; 2021-01-13 (163)/ 2021-01-16 (166)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031097; Age (Ye Gastrointestinal disorders/Dental caries/TOOTH DECAY	•	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Rotator cuff syndrome/ RIGHT ROTATOR CUFF TEAR	2020-08-24 (22)/ 2020-10-05 (64)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 135 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031097; Age (Y Cardiac disorders/Acute myocardial infarction, NON-ST ELEVATION MYOCARDIAL INFARCTION	2020-11-25 (115)/ / 2020-11-25 (115)	Race: Wi Yes/ Yes/ No	HITE 2	Yes/ 3 (2020-11-25/ 2020-11-27)		NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Cerebrovascular accident/ CEREBRAL VASCULAR ACCIDENT		Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031104; Age (Y Infections and infestations/ Tooth abscess/ ABSCESSED TOOTH	ears): 55; Gender: F; 2020-10-07 (69)/ 2020-10-07 (69)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 136 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
System Organ Class/	Start Date and Time (Relative Day)/	MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/ Verbatim	End Date and Time (Relative Day)	cited AR	Sev. [1]	Criteria [2]		Other Action Taken	Outcome
Subject ID: US2031105; Age (Y General disorders and administration site conditions/Fatigue/FATIGUE	ears): 67; Gender: F; 2020-06-28 (3)/ 2020-07-09 (14)	Race: W Yes/ No/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031108; Age (Y Gastrointestinal disorders/ Gastrooesophageal reflux disease/ ACID REFLUX		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031121; Age (Y General disorders and administration site conditions/ Peripheral swelling/ LOCALIZED SWELLING TO RIGHT LOWER EXTREMITY	2020-07-02 (3)/ 2020-07-15 (16)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 137 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) End Date and Time (Relative Day)	TEAE/ MAAE/ / Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031121; Age (Ye Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-11-22 (118)/ 2020-11-30 (126)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Gastrooesophageal reflux disease/ ACID REFLUX	2021-01-01 (158)/ 2021-02-12 (200)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Oral candidiasis/ ORAL CANDIDIASIS	2021-02-06 (194)/ 2021-02-23 (211)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 138 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/	Start Date and Time (Relative Day)/ End Date and	TEAE/ MAAE/ Soli- cited	Sev.	SAE/ Criteria	Relation- ship to	Action Taken with IP/ Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2041103; Age (Ye Investigations/ Platelet count decreased/ LOW PLATELETS	ears): 66; Gender: M; 2020-07-24 10:40 (28) ONGOING		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	UNKNOWN
Gastrointestinal disorders/ Oesophageal food impaction/ ESOPHAGEAL FOOD BOLUS OBSTRUCTION	, , ,	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Gastrooesophageal reflux disease/ GASTROESOPHAGEAL REFLUX DISEASE	2020-08-28 (36)/ 2020-10-15 (84)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 139 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041104; Age (Psychiatric disorders/ Insomnia/ INSOMNIA	Years): 68; Gender: F; 2020-07-01 (6)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2041109; Age (Infections and infestations/ Sinusitis/ SINUS INFECTION	Years): 66; Gender: F; 2020-12-25 (152)/ 2021-01-05 (163)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041119; Age (Nervous system disorders/ Nervous system cyst/ CYST ON SPINAL NERVE		Race: W Yes/ Yes/ No	HITE 1	Yes/ 3 (2020-11- 16/ 2020-11-1 7)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 140 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited S		SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041119; Age Musculoskeletal and connective tissue disorders/ Spondylolisthesis/ SPONDYLOLISTHESIS	(Years): 68; Gender: M; 2020-08-10 (7)/ 2020-11-16 (105)	Race: WHI Yes/ Yes/ No	1	Yes/ 3 (2020-11- 16/ 2020-11-1 7)		NOT APPLICABLE/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Endocrine disorders/ Hypothyroidism/ HYPOTHYROIDISM	2020-11-11 (100)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041145; Age Musculoskeletal and connective tissue disorders/ Arthritis/ RIGHT THUMB PIP ARTHRITI	2020-07-01 (-1)/ ONGOING	Race: WHI No/ 1 Yes/ No		No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 141 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041155; Age (Your Nervous system disorders/Headache/HEADACHE			HITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ DEPRESSION	2021-01-03 (154)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051057; Age (Musculoskeletal and connective tissue disorders/Arthralgia/JOINT ACHES IN SEVERAL JOINTS	Years): 61; Gender: F; 2020-06-26 (1)/ 2020-07-06 (11)	Race: W Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 142 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051057; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 61; Gender: F; 2020-06-26 (1)/ 2020-07-08 (13)	Race: WH Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-24 (1)/ 2020-07-31 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-24 (1)/ 2020-07-31 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 143 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051057; Age (Y General disorders and administration site conditions/ Injection site pain/ PAIN AT THE INJECTION SITE	ears): 61; Gender: F; 2020-07-24 10:00 (1); 2020-08-05 00:00 (12)	/ Yes/	HITE 2	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051059; Age (Y Skin and subcutaneous tissue disorders/ Rash/ SKIN RASH LEFT CHEEK ON FACE (UNKNOWN ETIOLOGY)	2020-09-10 (46)/ 2020-10-31 (97)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood cholesterol increased HIGH CHOLESTEROL	2020-12-17 (144)/ /ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 144 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051060; Age Eye disorders/ Cataract/ CATARACT RIGHT EYE	(Years): 65; Gender: F; 2020-10-09 (74)/ 2021-02-23 (211)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2051068; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 68; Gender: M; 2020-07-28 19:28 (1) 2020-08-04 19:05 (8)	/ Yes/	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES (IN SEVERAL JOINTS)	2020-07-28 19:28 (1) 2020-08-04 19:06 (8)	/Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 145 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					_
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2051068; Age (Y Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES (ALL OVER BODY)	2020-07-29 22:37 (2), 2020-08-04 19:06 (8)		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051071; Age (Y Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ ROTATOR CUFF PAIN	ears): 71; Gender: M; 2021-01-01 (159)/ 2021-02-08 (197)	Race: WH Yes/ Yes/ No	HITE 3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051092; Age (Y Injury, poisoning and procedural complications/ Muscle rupture/ TORN HAMSTRING RIGHT LEG	2020-11-10 (97)/	Race: WH Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 146 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051095; Age (Infections and infestations/Sinusitis/SINUS INFECTION	Years): 58; Gender: F; 2020-11-05 (99)/ 2020-11-18 (112)	Race: Why Yes/Yes/No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Periarthritis/ LEFT SHOULDER ADHESIVE CAPSULITIS	2021-01-10 (165)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2051103; Age (Note: Injury, poisoning and procedural complications/Arthropod bite/BUG BITE ON NECK	2020-07-03 (2)/	Yes/	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 147 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051103; Age (Y Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS BILATERA: ARMS AND BACK	2020-07-14 (13)/ 2020-07-22 (21)	Race: WH Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Neck pain/ NECK PAIN	2020-10-19 (82)/ 2021-04-30 (275)	Yes/ No/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051105; Age (Y Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	· · · · · · · · · · · · · · · · · · ·	Race: WH Yes/ No/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 148 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)		Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051109; Age (YEar and labyrinth disorders/Vertigo/WORSENING OF MEDICAL HISTOROF VERTIGO	2021-01-01 (151)/ ONGOING		ITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	UNKNOWN
Subject ID: US2061037; Age (Manager Age) Respiratory, thoracic and mediastinal disorders/ Rhinalgia/ NOSE PAIN	2020-06-26 00:00 (1)			HAWAIIAN (No	OR OTHER PA NR/R	CIFIC ISLANDER DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061053; Age (Musculoskeletal and connective tissue disorders/Plantar fasciitis/PLANTAR FASCIITIS - RIGHT	<pre>/ears): 64; Gender: F; 2020-07-10 (10)/ ONGOING</pre>	Race: WHI Yes/ No/ No		No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 149 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061068; Age (Y Nervous system disorders/ Dizziness/ DIZZINESS	· · · · · · · · · · · · · · · · · · ·	/Yes/	HITE 2	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Anxiety/ ANXIETY	2020-07-31 09:45 (31) 2020-07-31 14:30 (32)		2	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071025; Age (Y Nervous system disorders/ Syncope/ SYNCOPE OF UNCLEAR ORIGIN	•		HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-09 10:30 (1), 2020-07-10 08:00 (2)	/Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 150 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071083; Age (Your Vascular disorders/ Hypertension/ HYPERTENSION	<pre>//ears): 87; Gender: F; 2020-09-03 (45)/ ONGOING</pre>	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Cardiac disorders/ Bradycardia/ WORSENING OF BRADYCARDIA, CHRONIC	2020-09-03 (45)/ 2020-10-31 (103)	Yes/ Yes/ No	2	Yes/ 3 (2020-10-30/ 2020-10-3 1)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ MILD DEPRESSION	2020-10-14 (86)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Cardiac disorders/ Diastolic dysfunction/ GRADE 1 DIASTOLIC DYSFUNCTION	2020-10-30 (102)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 151 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071104; Age (Y Metabolism and nutrition disorders/ Hyperlipidaemia/ WORSENING OF HYPERLIPIDEMIA	2020-08-01 (27)/ ONGOING	Race: Wi Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Vascular disorders/ Hypertension/ HYPERTENSION	2020-08-01 (27)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Infections and infestations/ Bronchitis/ BRONCHITIS	2020-09-15 (37)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 152 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2071106; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	· · · · · · · · · · · · · · · · · · ·			No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081003; Age Ear and labyrinth disorders/ Excessive cerumen production/ EAR WAX BUILD UP	(Years): 64; Gender: F; 2020-08-13 (46)/ 2020-08-13 (46)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Infections and infestations/ Fungal skin infection/ TOE FUNGUS (LEFT BIG TOE)	2020-12-03 (158)/ 2021-02-26 (243)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 153 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081009; Age (Y Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS	ears): 59; Gender: F; 2020-07-02 13:30 (1), 2020-07-09 (8)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Tongue discomfort/ BURNING TONGUE SYNDROME	2020-09-30 (91)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING
Subject ID: US2081070; Age (Y Injury, poisoning and procedural complications/ Arthropod bite/ BED BUG BITES (BACK)	2020-08-10 (18)/	Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 154 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081071; Age (Y Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT WITH MUCUS	ears): 65; Gender: M; 2020-08-01 (4)/ 2020-08-03 (6)	Race: Why Yes/No/No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Pharyngeal erythema/ POSTERIOR OROPHARYNX SLIGHT ERYTHEMA (THROAT)	2020-08-05 (8)/ 2020-08-12 (15)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081092; Age (Y Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	ears): 77; Gender: F; 2020-07-02 (1)/ 2020-07-02 12:00 (1)	Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 155 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day End Date and Time (Relative Day	cited	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081092; Age (· · · · · · · · · · · · · · · · · · ·	•			· · · · ·		
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-02 (1)/ 2020-07-14 (13)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Dermatitis/ NONSPECIFIC DERMATITIS (RAS ACROSS FOREHEAD AND UPPER BACK)	2020-07-06 (5)/ 2020-07-12 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	2020-07-07 (6)/ 2020-07-07 (6)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 156 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081100; Age (Ye	ears): 59; Gender: F;	Race: W	HITE				
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-05 (4)/ 2020-07-05 (4)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-05 (4)/ 2020-07-11 (10)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site pruritus/ ITCHING AROUND INJECTION SITE, NO REDNESS	2020-08-05 (3)/ 2020-08-07 (5)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 157 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081100; Age (Young General disorders and administration site conditions/Fatigue/FATIGUE REPORTED BEYOND DAY 7 IN EDIARY	2020-08-05 (3)/ 2020-08-11 (9)	Race: W Yes/ No/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Anxiety/ WORSENING OF ANXIETY	2021-02-01 (183)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081118; Age (Yenal and urinary disorders/ Hypertonic bladder/ OVERACTIVE BLADDER	<pre>/ears): 70; Gender: F; 2020-07-10 (10)/ ONGOING</pre>	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 158 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081123; Age (Ye Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNITY ACQUIRED)	ears): 65; Gender: M; 2020-08-01 (33)/ 2020-08-26 (58)	Race: WH Yes/ Yes/ No	HITE 3	Yes/ 2, 3 (2020-08-01/ 2020-08-05)		DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood alkaline phosphatase increased/ ELEVATED ALKALINE PHOSPHATASE	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Investigations/ Platelet count increased/ ELEVATED PLATELET COUNT	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 159 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011004; Age (Y Nervous system disorders/ Syncope/ SYNCOPE	•	/Yes/	HITE 1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011028; Age (Y Metabolism and nutrition disorders/ Gout/ GOUT, RIGHT GREAT TOE	ears): 60; Gender: M; 2020-06-07 (7)/ 2020-06-16 (16)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Inguinal hernia/ HERNIA, LEFT INGUINAL	2020-10-30 (124)/ 2020-11-02 (127)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2011121; Age (Y Nervous system disorders/ Headache/ HEADACHE	•	Race: W Yes/ No/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 160 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
- ,	Start Date and	MAAE/		,		Action Taken	
System Organ Class/	Time (Relative Day)/		_	SAE/	Relation-	with IP/	
Preferred Term/ Verbatim	End Date and Time (Relative Day)	cited AR	Sev. [1]	Criteria [2]	ship to IP/SP [3]	Other Action Taken	Outcome
Subject ID: US2011121; Age (Ye Gastrointestinal disorders/Vomiting/VOMITTING		Race: W Yes/ No/ No	WHITE 2	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-08-13 (15)/ 2020-08-14 (16)	Yes/ No/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011122; Age (Ye Ear and labyrinth disorders/ Tinnitus/ TINNITUS, BILATERAL	ears): 59; Gender: F; 2021-02-20 (212)/ ONGOING	Race: W Yes/ Yes/ No	WHITE 1	No	NR/NR	NOT APPLICABLE/	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2011162; Age (You Skin and subcutaneous tissue disorders/ Ecchymosis/ ECCHYMOSIS, LT FOREARM	ears): 62; Gender: F; 2020-07-06 14:35 (1), 2020-07-14 08:00 (9)		VHITE 1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 161 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011162; Age (Skin and subcutaneous tissue disorders/ Pruritus/ BACK ITCH	(Years): 62; Gender: F; 2020-07-13 (8)/ 2020-07-22 (17)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Reproductive system and breast disorders/ Breast pain/ PAIN, RIGHT BREAST	2020-11-18 (108)/ 2021-01-20 (171)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Renal and urinary disorders/ Nephrolithiasis/ KIDNEY STONES	2021-01-18 (169)/ 2021-04-14 (255)	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 162 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011162; Age (Y Injury, poisoning and procedural complications/ Muscle strain/ PULLED MUSCLE, RIGHT PECTORAL	2021-01-20 (171)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021003; Age (Y Renal and urinary disorders/ Haematuria/ HEMATURIA	Tears): 58; Gender: M; 2020-10-06 (99)/ 2020-10-21 (114)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Metabolism and nutrition disorders/ Vitamin D deficiency/ VITAMIN D DEFICIENCY	2020-10-21 (114)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 163 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021011; Age (Y Gastrointestinal disorders/Diverticulum/DIVERTICULOSIS		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING
Eye disorders/ Glaucoma/ GLAUCOMA BILATERAL	2020-11-08 (136)/ 2020-11-08 (136)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED WITH SEQUELAE/ THIS WILL BE APART OF SUBJECT MEDICAL CONDITION
Subject ID: US2021031; Age (Y Cardiac disorders/ Arrhythmia/ ARRHYTHMIA	ears): 72; Gender: M; 2020-07-28 (30)/ 2020-07-30 (32)	Race: W Yes/ Yes/ No	HITE 4	Yes/ 3 (2020-07-28/ 2020-07-3 0)		NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Struck by lightning/ STRUCK BY LIGHTNING	2020-07-28 (30)/ 2020-07-30 (32)	Yes/ Yes/ No	3	Yes/ 3 (2020-07- 28/ 2020-07-3 0)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 164 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021115; Age Infections and infestations/ Otitis media/ RIGHT OTITIS MEDIA	(Years): 59; Gender: F; 2021-02-14 (199)/ 2021-02-18 (203)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Acute sinusitis/ ACUTE SINUSITIS	2021-02-14 (199)/ 2021-02-28 (213)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021208; Age Nervous system disorders/ Headache/ HEADACHE		/ Yes/	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 165 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021208; Age (Y Infections and infestations/ Pharyngitis/ PHARYNGITIS	ears): 56; Gender: F; 2020-08-04 (7)/ 2020-08-07 (10)	Race: WH Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/Rhinorrhoea/NASAL DRAINAGE (UNKNOWN)	2020-08-04 (7)/ 2020-08-07 (10)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-08-04 (7)/ 2020-08-07 (10)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Plantar fasciitis/ PLANTAR FASCIITIS	2020-09-14 (48)/ 2020-09-22 (56)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 166 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	- ,	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021211; Age (Y	ears): 78; Gender: F;	Race: WH	HITE				
Infections and	2020-07-21 (20)/	Yes/	2	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2020-07-27 (26)	Yes/				CHANGED/	RESOLVED
Tooth infection/		No				CONCOMITANT	
INFECTION FROM FILLING IN						MEDICATION	
TOOTH							
Gastrointestinal disorders/	2020-12-19 (142)/	Yes/	2	No	NR/NR	DOSE NOT	RECOVERED/
Gastrooesophageal reflux	2020-12-20 (143)	Yes/				CHANGED/	RESOLVED
disease/		No				CONCOMITANT	
WORSENING OF						MEDICATION	
GASTROESOPHAGEAL REFLUX							
DISEASE							
Subject ID: US2021214; Age (Y	ears): 73; Gender: F;	Race: WH	HITE				
Injury, poisoning and	2020-07-14 (19)/	Yes/	2	No	NR/NR	DOSE NOT	RECOVERED/
procedural complications/	2020-07-29 (34)	No/				CHANGED/	RESOLVED
Joint injury/		No				CONCOMITANT	
RE-INJURED RIGHT HIP						MEDICATION	

Notes listed on the last page.

Page 167 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021214; Age (Seneral disorders and administration site conditions/Fatigue/FATIGUE	Years): 73; Gender: F; 2020-09-09 (48)/ 2020-09-12 (51)	Race: Why Yes/No/No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/Chills/CHILLS	2020-09-10 (49)/ 2020-09-11 (50)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pyrexia/ FEVER	2020-09-10 (49)/ 2020-09-11 (50)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 168 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021214; Age General disorders and administration site conditions/ Pain/ GENERALIZED BODY ACHES	2020-09-10 (49)/	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021218; Age Immune system disorders/ Seasonal allergy/ WORSENING OF SEASONAL ALLERGIES			HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021230; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 68; Gender: F; 2020-12-23 (143)/ 2021-02-05 (187)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 169 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021234; Age (Musculoskeletal and connective tissue disorders/ Neck pain/ WORSENING OF NECK PAIN	(Years): 70; Gender: F; 2020-08-12 (9)/ 2020-10-01 (59)	Race: W Yes/ No/ No	WHITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041112; Age (Investigations/ Blood pressure diastolic increased/ ELEVATED DIASTOLIC BLOOD PRESSURE GRADE 0 TO GRADE 2 POST VACCINATION	2020-06-26 14:17 (1)	/ Yes/	WHITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 170 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
	Start Date and	MAAE/		/		Action Taken	
System Organ Class/	Time (Relative Day)/		~	SAE/	Relation-	- ,	
Preferred Term/ Verbatim	End Date and Time (Relative Day)	cited AR	Sev. [1]	Criteria [2]	ship to IP/SP [3]	Other Action Taken	Outcome
				[2]	11/51 [5]	1aven	Outcome
Subject ID: US2041122; Age (General disorders and administration site conditions/ Injection site erythema/ CIRCUMFERENTIAL REDNESS ABOVE INJECTION SITE ON LEFT ARM	Years): 82; Gender: F; 2020-07-08 (10)/ 2020-07-16 (18)	Yes/ No/ No	MHITE 1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041126; Age (Nervous system disorders/ Headache/ HEADACHE		Race: Yes/ No/ Yes	WHITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051069; Age (Infections and infestations/ Gastroenteritis viral/ STOMACH VIRUS	Years): 64; Gender: F; 2020-08-18 (22)/ 2020-08-20 (24)	Race: Yes/ No/ No	WHITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 171 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051084; Age (Nervous system disorders/ Dysgeusia/ DYSGUESIA		Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051088; Age (Musculoskeletal and connective tissue disorders/ Back pain/ BACK PAIN	Years): 58; Gender: M; 2020-08-01 (5)/ 2020-08-02 (6)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051108; Age (Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS RIGHT FOREARM AND RIGHT THIGH	Years): 65; Gender: M; 2020-07-16 (11)/ 2020-08-17 (43)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 172 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061036; Age (Infections and infestations/ Nasopharyngitis/ COMMON COLD	Years): 56; Gender: F; 2020-10-30 (96)/ ONGOING	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2071013; Age (Investigations/Blood pressure increased/ELEVATED BLOOD PRESSURE WITHOUT DIAGNOSIS OF HYPERTENSION	2021-01-19 (195)/	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071043; Age (Injury, poisoning and procedural complications/Meniscus injury/ LEFT MEDIAL MENISCUS TEAR	2020-08-01 (27)/	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 173 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
System Organ Class/	Start Date and Time (Relative Day)/	MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071082; Age (Y Skin and subcutaneous tissue disorders/ Erythema/ ERYTHEMA LEFT METATARSOPHALANGEAL JOINTS	2020-08-18 (22)/ 2020-09-02 (37)	Race: W. Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Arthralgia/ TENDERNESS LEFT METATARSOPHALANGEAL JOINTS	2020-08-18 (22)/ 2020-09-02 (37)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071087; Age (Y Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-09-28 (61)/ 2020-10-04 (67)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 174 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2071093; Age (Y General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE	ears): 67; Gender: F; 2020-06-30 (2)/ 2020-07-02 (4)	Race: W Yes/ No/ No	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081001; Age (Y General disorders and administration site conditions/ Pyrexia/ UNREPORTED FEVER OF 101.4	ears): 57; Gender: M; 2020-06-25 06:00 (1), 2020-06-25 09:00 (2)		HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081014; Age (Y Investigations/ White blood cell count decreased/ LOW WHITE BLOOD CELL COUNT	ears): 67; Gender: F; 2020-06-30 09:20 (29) 2020-07-28 09:13 (57)	/Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 175 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081014; Age (Y Injury, poisoning and procedural complications/ Concussion/ CONCUSSION	2020-08-22 (54)/	Race: W. Yes/ Yes/ No	HITE 3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081016; Age (Y Infections and infestations/ Sinusitis/ SINUS INFECTION	Tears): 55; Gender: F; 2020-07-14 (16)/2020-07-23 (25)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081069; Age (Y General disorders and administration site conditions/ Injection site mass/ LUMP AT INJECTION SITE	Tears): 70; Gender: F; 2020-06-27 (2)/ONGOING	Race: W Yes/ No/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 176 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081069; Age (Y Nervous system disorders/ Sinus headache/ SINUS HEADACHE		Race: Wi Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081072; Age (Y Immune system disorders/ Seasonal allergy/ WHEEZING (SEASONAL ALLERGY RELATED)	2020-07-03 (8)/		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081076; Age (Y General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE (DAY 8)	ears): 55; Gender: F; 2020-08-05 (1)/ 2020-08-13 (9)	Race: W. Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 177 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081076; Age (Y General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE (DAY 8)	ears): 55; Gender: F; 2020-08-05 (1)/ 2020-08-13 (9)	Race: W Yes/ No/ Yes	HITE 1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081081; Age (Y Injury, poisoning and procedural complications/ Tendon rupture/ TORN ACHILLES (LEFT FOOT)	2021-01-06 (162)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Vascular disorders/ Hypertension/ HYPERTENSION	2021-01-27 (183)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 178 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081088; Age (Y Musculoskeletal and connective tissue disorders/ Musculoskeletal chest pain/ CHEST TIGHTNESS (MUSCULOSKELETAL)	2020-07-07 (6) / 2020-07-07 (6)	Race: W Yes/ No/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081093; Age (Y Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	ears): 66; Gender: F; 2020-07-03 (2)/ 2020-07-03 12:00 (2)	Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 179 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	_	Other Action	
<u>Verbatim</u>	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081093; Age (Y Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	ears): 66; Gender: F; 2020-07-09 (8)/ 2020-07-09 (8)	Race: WI Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081099; Age (Y Musculoskeletal and connective tissue disorders/ Arthralgia/ GENERALIZED JOINT ACHES (DAY 8-DAY 14 AFTER INJECTION)	2020-07-29 (1)/ 2020-08-11 (14)	Race: WI Yes/ No/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE (DAY 8 AFTER INJECTION)	2020-08-06 (9)/ 2020-08-08 (11)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 180 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081120; Age (Investigations/ Haematocrit increased/ CS HEMATOCRIT LAB (INCREASED)	Years): 72; Gender: M; 2020-07-29 (1)/ ONGOING	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
<pre>Investigations/ Haemoglobin increased/ CS HEMOGLOBIN LAB (INCREASED)</pre>	2020-07-29 (1)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Reproductive system and breast disorders/ Prostatomegaly/ ENLARGED PROSTATE	2020-12-01 (126)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 181 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081121; Age (Ye Respiratory, thoracic and mediastinal disorders/Oropharyngeal pain/SORE THROAT	ears): 63; Gender: F; 2020-07-09 (4)/ 2020-07-11 (6)	Race: WI Yes/ No/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Musculoskeletal stiffness/ STIFF NECK	2020-07-09 (4)/ 2020-07-11 (6)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Aphthous ulcer/ CANKER SORE	2020-07-09 (4)/ 2020-07-15 (10)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-13 (8)/ 2020-07-15 (10)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 182 of 184 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081121; Age (Young Musculoskeletal and connective tissue disorders/ Musculoskeletal stiffness/ STIFF NECK	Years): 63; Gender: F; 2020-07-13 (8)/ 2020-07-15 (10)	Race: W Yes/ No/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE POS DOSE		/Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081129; Age (Y Nervous system disorders/ Dizziness/ DIZZINESS	•		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 183 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) End Date and Time (Relative Day)	cited	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081129; Age (Seneral disorders and administration site conditions/Malaise/MALAISE	Years): 58; Gender: F 2020-08-10 (8)/ 2020-08-10 (8)	Yes/ Yes/ No	VHITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Chemical burn/ CHEMICAL BURN (MIDDLE STERNUM AND LEFT LATERAL SUPERIOR CHEST)	2020-12-08 (128)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 184 of 184
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.7 Unsolicited Adverse Events Safety Set

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date. MedDRA version $23.0\,$

- [1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.
- [2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.
- [3] R = Related, NR = Not Related, NA = Not Applicable.

Page 1 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
		•					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome

There are no observations for this section.

Notes listed on the last page.

Page 2 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) / End Date and Time (Relative Day)	cited		SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041007; Age (Ye Pregnancy, puerperium and perinatal conditions/ Abortion spontaneous/ SPONTANEOUS ABORTION	2020-12-17 (172)/	Race: W Yes/ Yes/ No	HITE 1	Yes/	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 3 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		$\mathtt{TEAE}/$					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011089; Age (Y	<pre>//ears): 32; Gender: F;</pre>	Race: W	HITE				
Pregnancy, puerperium and	2021-02-26 (232)/	Yes/	2	Yes/	NR/NR	NOT APPLICABLE/	RECOVERED/
perinatal conditions/	2021-03-10 (244)	Yes/		6		CONCOMITANT	RESOLVED
Abortion missed/		No				PROCEDURE	
MISCARRIAGE (MISSED							
ABORTION)							

Notes listed on the last page.

Page 4 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

		TEAE/					
		•					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome

There are no observations for this section.

Notes listed on the last page.

Page 5 of 8 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031097; Age (Y Cardiac disorders/ Acute myocardial infarction NON-ST ELEVATION MYOCARDIAL INFARCTION	2020-11-25 (115)/ / 2020-11-25 (115)	Race: Wi Yes/ Yes/ No	HITE 2	Yes/ 3 (2020-11-25/ 2020-11-27)		NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041119; Age (Y Nervous system disorders/ Nervous system cyst/ CYST ON SPINAL NERVE		Yes/	HITE 1	Yes/ 3 (2020-11- 16/ 2020-11-1 7)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Spondylolisthesis/ SPONDYLOLISTHESIS	2020-08-10 (7)/ 2020-11-16 (105)	Yes/ Yes/ No	1	Yes/ 3 (2020-11- 16/ 2020-11-1 7)		NOT APPLICABLE/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 6 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071083; Age (Y Cardiac disorders/ Bradycardia/ WORSENING OF BRADYCARDIA, CHRONIC	ears): 87; Gender: F; 2020-09-03 (45)/ 2020-10-31 (103)	Race: W Yes/ Yes/ No	HITE 2	Yes/ 3 (2020-10-30/ 2020-10-3 1)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2081123; Age (Y Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNITY ACQUIRED)	2020-08-01 (33)/ 2020-08-26 (58)	Race: W Yes/ Yes/ No	HITE 3	Yes/ 2, 3 (2020-08-01/ 2020-08-05)		DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 7 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021031; Age (Y Cardiac disorders/ Arrhythmia/ ARRHYTHMIA	ears): 72; Gender: M; 2020-07-28 (30)/ 2020-07-30 (32)	Race: WH Yes/ Yes/ No	HITE 4	Yes/ 3 (2020-07-28/ 2020-07-3 0)		NOT APPLICABLE/	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Struck by lightning/ STRUCK BY LIGHTNING	2020-07-28 (30)/ 2020-07-30 (32)	Yes/ Yes/ No	3	Yes/ 3 (2020-07- 28/ 2020-07-3 0)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 8 of 8
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.8 Serious Adverse Events Safety Set

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date. MedDRA version $23.0\,$

- [1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.
- [2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.
- [3] R = Related, NR = Not Related, NA = Not Applicable.

Page 1 of 2
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.10

Unsolicited Adverse Events Leading to Discontinuation from Participation in the Study Safety Set

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome

There are no observations for this listing.

Notes listed on the last page.

Page 2 of 2
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.10

Unsolicited Adverse Events Leading to Discontinuation from Participation in the Study Safety Set

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date. MedDRA version $23.0\,$

- [1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.
- [2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.
- [3] R = Related, NR = Not Related, NA = Not Applicable.

Page 1 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011056; Age (Ye Reproductive system and breast disorders/ Testicular cyst/ BENIGN CYST, LEFT TESTICLE	ears): 30; Gender: M; 2020-09-05 (68)/ ONGOING	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2011060; Age (Yes) Skin and subcutaneous tissue disorders/ Dermatitis contact/ EXASPERATION OF POISON IVY RASH LEFT FOREARM/RIGHT UPPER THIGH	ears): 49; Gender: F; 2020-06-06 (5)/ 2020-06-13 (12)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Toothache/ TOOTH PAIN, LEFT LOWER SECOND MOLAR (FROM ROOT CANAL)	2020-07-23 (24)/ 2020-07-30 (31)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 2 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2011067; Age (Y	(ears): 28; Gender: F;	Race: B	BLACK C	R AFRICAN	AMERICAN		
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-06-09 (7)/ 2020-07-17 (45)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Dry throat/ DRY THROAT	2020-06-09 (7)/ 2020-07-30 (58)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-11-06 (123)/ 2020-11-15 (132)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-11-06 (123)/ 2020-11-16 (133)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 3 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011067; Age (Y General disorders and administration site conditions/ Pain/ BODY ACHES	Years): 28; Gender: F; 2020-11-07 (124)/ 2020-11-15 (132)	Race: B Yes/ Yes/ No	LACK O	R AFRICAN No	AMERICAN NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RUNNY NOSE	2020-11-08 (125)/ 2020-11-16 (133)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011088; Age (Y Injury, poisoning and procedural complications/ Tendon injury/ LEFT LACERATED GREAT TOE TENDON	2021-01-15 (193)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 4 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021073; Age (Y Gastrointestinal disorders/ Oral disorder/ LESION ON GUM (UNKNOWN) BENGIN		Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2020-12-05 (159)/ 2020-12-20 (174)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021082; Age (You General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 47; Gender: M; 2020-09-06 (62)/ 2020-09-11 (67)	Race: WH Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 5 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021082; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 47; Gender: M; 2020-09-10 (66)/ 2020-10-08 (94)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood testosterone decreased/ LOW TESTOSTERONE	2020-10-15 (101)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Investigations/ Vitamin D decreased/ LOW VITAMIN D	2020-10-17 (103)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Endocrine disorders/ Hyperoestrogenism/ HYPERESTROGENISM	2020-12-14 (161)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 6 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/				
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited Sev AR [1]	SAE/ . Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021094; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	(Years): 53; Gender: M; 2020-07-06 (32)/ 2020-07-23 (49)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021111; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 36; Gender: F; 2020-07-10 (33)/ 2020-07-17 (40)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Suspected COVID-19/ COVID 19 LIKE ILLNESS	2021-01-20 (184)/ 2021-01-25 (189)	Yes/ 1 Yes/ No	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 7 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021111; Age Musculoskeletal and connective tissue disorders/ Bursitis/ BURSITIS LEFT SHOULDER	(Years): 36; Gender: F; 2021-02-01 (196)/ 2021-02-08 (203)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021137; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	(Years): 26; Gender: M; 2020-07-07 15:39 (29) 2020-07-15 14:00 (37	/Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021138; Age Infections and infestations/ Suspected COVID-19/ COVID 19 LIKE ILLNESS	(Years): 52; Gender: F; 2021-02-06 (216)/ 2021-02-17 (227)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 8 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021155; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 46; Gender: M; 2020-08-17 (36)/ 2020-09-23 (73)		HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021175; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 36; Gender: F; 2020-10-12 (97)/ 2020-11-01 (117)		HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031041; Age Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTI	2020-07-05 (5)/ 2020-07-11 (11)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 9 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031049; Age (Yespeniatric disorders/Anxiety/ANXIETY	Years): 37; Gender: F;	Race: W Yes/ Yes/ No		No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ DEPRESSION	2020-12-08 (161)/ 2021-02-02 (217)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031074; Age (1) Infections and infestations/ Otitis media/ BILATERAL ACUTE OTITIS MEDI	2020-06-10 (9)/ 2020-06-19 (18)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 10 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031074; Age (Your Infections and infestations/ Sinusitis/ SINUS INFECTION	ears): 52; Gender: F; 2020-06-10 (9)/ 2020-06-19 (18)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2021-02-05 (221)/ 2021-02-15 (231)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041019; Age (Year) Injury, poisoning and procedural complications/ Skin laceration/ LEFT HAND LACERATION	2020-07-06 (7)/	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 11 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041022; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 40; Gender: F; 2020-10-31 (118)/ 2020-11-15 (133)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041056; Age Skin and subcutaneous tissue disorders/ Acne/ GENERALIZED ACNE	(Years): 23; Gender: M; 2021-02-08 (224)/ ONGOING		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051022; Age Infections and infestations/ Localised infection/ TOE INFECTION RIGHT FOOT (2-4 DIGITS)	(Years): 22; Gender: F; 2020-12-04 (151)/ 2021-01-14 (192)	Race: W Yes/ Yes/ No	HITE 2	No	R/R	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 12 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051035; Age Infections and infestations/COVID-19/POSITIVE COVID 19 INFECTION	2020-09-03 (58)/ 2021-03-26 (262)		WHITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061003; Age Infections and infestations/ COVID-19/ COVID - 19 INFECTION			WHITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061018; Age Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-11-28 (144)/ 2020-12-01 (147)		VHITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 13 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061018; Age (Ye Infections and infestations/COVID-19/COVID-19 POSITIVE INFECTION	ears): 50; Gender: F; 2020-12-01 (147)/ 2020-12-05 (151)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061024; Age (Year Respiratory, thoracic and mediastinal disorders/Dyspnoea/SHORTNESS OF BREATH - NOS	2020-11-25 (147)/	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071012; Age (Ye Infections and infestations/COVID-19/COVID 19 INFECTION	ears): 40; Gender: F; 2020-12-04 (151)/ 2020-12-16 (163)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 14 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071044; Age (Young Metabolism and nutrition disorders/Vitamin D deficiency/VITAMIN D DEFICIENCY	<pre>/ears): 32; Gender: F; 2021-01-28 (204)/ ONGOING</pre>	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071050; Age (Y Infections and infestations/ Gingivitis/ GINGIVITIS	<pre>//ears): 45; Gender: M; 2020-12-04 (151)/ 2020-12-14 (161)</pre>	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-12-04 (151)/ 2020-12-18 (165)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 15 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	-	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071062; Age (Y Infections and infestations/ COVID-19/ COVID-19 INFECTION	ears): 29; Gender: M; 2020-11-24 (141)/ 2020-11-30 (147)	Race: WI Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071066; Age (Y Gastrointestinal disorders/Diverticulum/DIVERTICULOSIS	· · · · · · · · · · · · · · · · · · ·	Race: Will Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERING/ RESOLVING
Subject ID: US2071070; Age (Y Infections and infestations/ COVID-19/ COVID 19 INFECTION	ears): 34; Gender: F; 2020-12-11 (158)/ 2021-02-02 (211)	Race: Why Yes/Yes/No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 16 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071072; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 39; Gender: F; 2020-11-30 (148)/ 2020-12-11 (159)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081033; Age Infections and infestations/ Otitis externa/ SWIMMER'S EAR (LEFT EAR)	(Years): 43; Gender: F; 2020-07-13 (7)/ 2020-07-18 (12)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2021-01-05 (183)/ 2021-03-15 (252)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 17 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events

Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081038; Age (Y	<pre>Years): 30; Gender: M;</pre>	Race: W	HITE				
Injury, poisoning and	2020-06-08 14:00 (1)	/Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
procedural complications/	2020-06-15 (8)	Yes/				CHANGED/	RESOLVED
Skin laceration/		No				CONCOMITANT	
CUT ON LEFT FOREARM						MEDICATION,	
						CONCOMITANT	
						PROCEDURE	
Subject ID: US2081046; Age (Y	<pre>/ears): 45; Gender: M;</pre>	Race: W	HITE				
Skin and subcutaneous	2020-06-08 (1)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
tissue disorders/	2020-06-16 (9)	Yes/				CHANGED/	RESOLVED
Rash papular/		No				NONE	
PAPULAR RASH ON FOREARM							
(BILATERAL)							

Notes listed on the last page.

Page 18 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081046; Age (Infections and infestations/ COVID-19/ CONFIRMED COVID 19 INFECTION (SYMPTOMATIC- FEVER, HEADACHE, HEAVY FEELING IN CHEST, BODY ACHES)	2020-10-06 (90)/ 2020-11-06 (121)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081049; Age (Infections and infestations/ Gastroenteritis/ GASTROENTERITIS	Years): 47; Gender: F; 2020-07-17 (10)/ 2020-07-28 (21)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-27 (20)/ 2020-08-03 (27)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 19 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					_
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081049; Age (Years): 47; Gender: F;	Race: WI	HITE				
Infections and	2020-08-05 (29)/	Yes/	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/
infestations/	2020-08-12 (36)	Yes/				CONCOMITANT	RESOLVED
Oral candidiasis/		No				MEDICATION	
THRUSH (TONGUE)							
Psychiatric disorders/	2020-11-17 (133)/	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
Anxiety/	2020-12-22 (168)	Yes/				CONCOMITANT	RESOLVED
WORSENING OF ANXIETY		No				MEDICATION	
Subject ID: US2081058; Age (Years): 20; Gender: F;	Race: WI	HITE				
Infections and	2020-11-16 (162)/	Yes/	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/
infestations/	2020-12-02 (178)	Yes/				NONE	RESOLVED
Sinusitis/		No					
SINUS INFECTION							

Notes listed on the last page.

Page 20 of 95
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Da End Date and Time (Relative Da	MA y)/ Sc ci		Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011051; Age (Y Skin and subcutaneous tissue disorders/ Rash/ ALL OVER BODY RASH	ears): 20; Gender: 2020-06-22 (21)/ 2020-07-02 (31)	Ye	es/ es/	ITE 2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/Rhinorrhoea/RUNNY NOSE	2020-10-15 (102)/ 2020-10-25 (112)		es/ es/	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Sneezing/ SNEEZING	2020-10-16 (103)/ 2020-10-22 (109)		es/ es/	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Dizziness/ LIGHTHEADEDNESS	2020-10-17 (104)/ 2020-10-20 (107)		es/ es/	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 21 of 95
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (Yes) General disorders and administration site conditions/ Fatigue/ FATIGUE	<pre>Zears): 20; Gender: F; 2020-10-17 (104)/ 2020-10-28 (115)</pre>	Race: Why Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Ageusia/ LOSS OF TASTE	2020-10-17 (104)/ 2020-10-30 (117)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Dizziness/ DIZZINESS	2020-10-18 (105)/ 2020-10-23 (110)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pain/ BODY ACHES	2020-10-18 (105)/ 2020-10-28 (115)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 22 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (Ye Respiratory, thoracic and mediastinal disorders/Cough/COUGH		Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-10-19 (106)/ 2020-10-28 (115)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/Road traffic accident/CAR ACCIDENT	2020-11-19 (137)/ 2020-11-19 (137)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Post-traumatic pain/ BACK PAIN, SECONDARY TO CAR ACCIDENT	2020-11-19 (137)/ 2020-12-15 (163)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 23 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (Year) Injury, poisoning and procedural complications/ Post-traumatic pain/ NECK PAIN SECONDARY TO CAR ACCIDENT	2020-11-19 (137)/	Race: Will Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011084; Age (Yes) Skin and subcutaneous tissue disorders/ Dermatitis contact/ MACULOPAPULAR RASH ON CHEST AND ABDOMEN, ALLERGIC REACTION TO NEW SOAP	ears): 49; Gender: M; 2020-07-01 06:00 (1), 2020-07-13 (14)		HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2011087; Age (Yellow) Psychiatric disorders/ Anxiety/ ANXIETY	•	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 24 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011087; Age (Yet Psychiatric disorders/ Insomnia/ TROUBLE SLEEPING, DUE TO ANXIETY	ears): 33; Gender: M; 2021-01-01 (185)/ ONGOING	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2011091; Age (You Vascular disorders/ Hypertension/ HYPERTENSION	ears): 54; Gender: F; 2020-10-05 (96)/ ONGOING	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Respiratory, thoracic and mediastinal disorders/ Dyspnoea/ SHORTNESS OF BREATH	2020-11-19 (141)/ 2020-11-21 (143)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-11-19 (141)/ 2020-11-21 (143)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 25 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011091; Age (Y Nervous system disorders/ Headache/ HEADACHE		Race: W Yes/ Yes/ No		No	NR/NR	NOT APPLICABLE/	
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-11-19 (141)/ 2020-11-23 (145)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/Chills/CHILLS	2020-11-21 (143)/ 2020-11-22 (144)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 26 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011092; Age (Y Gastrointestinal disorders/ Gastritis/ GASTRITIS	•	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Infections and infestations/ Bronchitis/ BRONCHITIS	2020-11-20 (137)/ 2020-12-02 (149)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011102; Age (Y Injury, poisoning and procedural complications/ Meniscus injury/ TORN MINISCUS, LEFT KNEE	2020-09-01 (58)/	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 27 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011102; Age (Y Injury, poisoning and procedural complications/ Procedural pain/ POST-OPERATIVE PAIN, TORN LEFT KNEE MENISCUS	2020-11-30 (148)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021058; Age (Y Injury, poisoning and procedural complications/ Tooth fracture/ BROKEN TOOTH RIGHT MOLAR	2020-07-22 (16)/	Race: W. Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2021090; Age (Y Nervous system disorders/ Tension headache/ WORSENING OF TENSION HEADACHE		Race: W. Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 28 of 95
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021166; Age (Y Injury, poisoning and procedural complications/ Breast injury/ RIGHT BREAST INJURY	2020-11-29 (146)/	Race: O'Yes/ Yes/ No	THER: 3	ASHKENAZI No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Psychiatric disorders/ Anxiety/ WORSENING OF ANXIETY	2021-01-20 (198)/ 2021-02-10 (219)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Psychiatric disorders/ Insomnia/ WORSENING OF INSOMNIA	2021-01-20 (198)/ 2021-02-10 (219)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Psychiatric disorders/ Major depression/ WORSENING OF MAJOR DEPRESSIVE DISORDER	2021-01-20 (198)/ 2021-02-10 (219)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 29 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021167; Age (Yes) Blood and lymphatic system disorders/ Lymphadenopathy/ LEFT ANTERIOR CERVICAL CHAIN LYMPH NODE	2021-01-04 (182)/ 2021-01-11 (189)	Race: Will Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021179; Age (Yes) Skin and subcutaneous tissue disorders/ Acne/ ACNE BUTTOCKS	ears): 38; Gender: F; 2020-09-19 (75)/ 2020-11-01 (118)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Abdominal pain/ ABDOMINAL PAIN	2020-10-04 (90)/ 2020-10-07 (93)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-10-04 (90)/ 2020-10-07 (93)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 30 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031004; Age Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	(Years): 31; Gender: F; 2020-07-12 (14)/ 2020-07-22 (24)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031016; Age Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION			HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031056; Age Infections and infestations/ Infected bite/ LEFT KNEE INFECTION FROM B BITE	2020-08-26 (58)/ 2020-09-07 (70)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 31 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031072; Age (YIN) Injury, poisoning and procedural complications/ Foreign body in eye/ RIGHT EYE IRRITATION SECONDARY TO FOREIGN OBJECT IN EYE	2020-06-17 (15)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Vascular disorders/ Hypertension/ HYPERTENSION	2021-01-25 (204)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041007; Age (Y Pregnancy, puerperium and perinatal conditions/ Abortion spontaneous/ SPONTANEOUS ABORTION	Years): 33; Gender: F; 2020-12-17 (172)/ 2020-12-17 (172)	Race: W Yes/ Yes/ No	HITE 1	Yes/	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 32 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/ Preferred Term/	Start Date and Time (Relative Day) / End Date and	cited	Sev.	SAE/ Criteria	-	Action Taken with IP/ Other Action	Outrous
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2041016; Age (Infections and infestations/Viral infection/VIRAL SYNDROME OF UNKNOWN ETIOLOGY	Years): 39; Gender: M; 2020-12-09 (149)/ 2021-01-21 (192)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NA	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041023; Age () Infections and infestations/ Viral infection/ VIRAL SYNDROME OF UNKNOWN ETIOLOGY	Years): 53; Gender: F; 2020-09-24 (88)/ 2020-10-02 (96)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041027; Age (Infections and infestations/Viral infection/VIRAL SYNDROME OF UNKNOWN ETIOLOGY	Years): 40; Gender: F; 2020-12-05 (160)/ 2020-12-11 (166)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 33 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2041047; Age (Y	ears): 33; Gender: M;	Race: W	HITE				
Infections and	2020-08-04 (36)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2020-08-13 (45)	Yes/				CHANGED/	RESOLVED
COVID-19/		No				NONE	
COVID-19 INFECTION							
Subject ID: US2041049; Age (Y	ears): 23; Gender: F;	Race: W	HITE				
Nervous system disorders/			1	No	NR/NR	DOSE NOT	RECOVERING/
Tremor/	ONGOING	Yes/				CHANGED/	RESOLVING
BILATERAL LEG TREMORS		No				NONE	
Subject ID: US2041051; Age (Y	ears): 25; Gender: F;	Race: W	HITE				
-	2020-10-16 (109)/		1	No	NR/NR	NOT APPLICABLE/	RECOVERING/
disorders/	ONGOING	Yes/				CONCOMITANT	RESOLVING
Vitamin B12 deficiency/		No				MEDICATION	
VITAMIN B12 DEFICIENCY							

Notes listed on the last page.

Page 34 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age \geq 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (YInfections and infestations/ Eye infection/ BILATERAL EYE INFECTION	ears): 40; Gender: F; 2020-10-19 (106)/ 2020-11-16 (134)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041077; Age (Your Nervous system disorders/ Paraesthesia/ BILATERAL NUMBNESS/TINGLING IN HANDS	2020-07-05 (5)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE	2020-07-14 (14)/ ONGOING	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 35 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041092; Age (Your Vascular disorders/ Hypertension/ HYPERTENSION	· · · · · · · · · · · · · · · · · · ·	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051010; Age (YINTERCOMMENT OF THE STATE OF THE SUBJECT OF THE SUBJ	Years): 42; Gender: F; 2020-06-14 (13)/ 2020-08-03 (63)	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051011; Age (Yangury, poisoning and procedural complications/Epicondylitis/TENNIS ELBOW BILATERAL	2020-08-21 (46)/	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 36 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2051018; Age (Yangury, poisoning and procedural complications/Corneal abrasion/LEFT CORNEAL ABRASION	2020-10-13 (99)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051034; Age (YIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	2020-06-09 (7)/ 2020-06-15 (13)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051040; Age (Your Skin and subcutaneous tissue disorders/Dermatitis contact/CONTACT DERMATITIS (THIGHS, TRUNK, FOREARMS, ANKLES)	2020-06-20 (16)/ 2020-06-27 (23)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 37 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051042; Age (YINFections and infestations/Urethritis/URETHRITIS	<pre>//ears): 35; Gender: M; 2020-08-16 (47)/ 2020-08-21 (52)</pre>	Race: W Yes/ Yes/ No	HITE 3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Staphylococcus test positive/ STAPH POSITIVE URINALYSIS	2020-09-16 (78)/ 2020-09-30 (92)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051043; Age (Y Nervous system disorders/ Headache/ HEADACHE		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2061001; Age (Y Gastrointestinal disorders/ Gastritis/ GASTRITIS		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 38 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	ship to	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061006; Age Infections and infestations/ Herpes zoster/ SHINGLES	(Years): 35; Gender: F; 2021-01-18 (202)/ 2021-01-25 (209)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061009; Age Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-10-05 (91)/ 2020-10-10 (96)	Race: W Yes/ Yes/ No	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061019; Age Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT		Race: W Yes/ Yes/ No	HITE 2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 39 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061026; Age (Naspiratory, thoracic and mediastinal disorders/Nasal congestion/NASAL CONGESTION	Years): 43; Gender: M; 2020-09-14 (70)/ 2020-09-18 (74)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-09-15 (71)/ 2020-09-18 (74)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071001; Age (Yes) Psychiatric disorders/ Anxiety/ ANXIETY	•	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 40 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071001; Age Infections and infestations/ Sinusitis/ SINUS INFECTION	(Years): 28; Gender: F; 2020-09-11 (74)/ 2020-09-15 (78)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATIORY INFECTION	2020-12-26 (180)/ 2021-01-19 (204)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071004; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 39; Gender: M; 2020-07-09 (2)/ 2020-07-16 (9)	Race: Wi Yes/ Yes/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 41 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071004; Age (Y Nervous system disorders/ Headache/ HEADACHE	ears): 39; Gender: M; 2020-07-09 08:00 (1) 2020-07-16 (9)		HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-14 (7)/ 2020-07-15 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATORY INFECTION	2020-10-14 (99)/ 2020-10-16 (101)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 42 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/	Start Date and Time (Relative Day)/	MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/ Verbatim	End Date and Time (Relative Day)	cited AR	Sev. [1]	Criteria [2]	ship to IP/SP [3]	Other Action Taken	Outcome
Subject ID: US2071030; Age Infections and infestations/ Tinea pedis/ WORSENING OF TINEA PEDIS LEFT BIG TOE	(Years): 37; Gender: F; 2020-09-27 (84)/ 2020-12-31 (179)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071074; Age Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATORY INFECTION	(Years): 40; Gender: F; 2020-12-06 (151)/ 2020-12-23 (168)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Subject ID: US2081036; Age Nervous system disorders/ Migraine/ WORSENING OF MIGRAINES		Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 43 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081036; Age (Y Infections and infestations/ COVID-19/ COVID 19 INFECTION	Tears): 48; Gender: M; 2020-12-15 (160)/ 2020-12-25 (170)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081041; Age (Y Respiratory, thoracic and mediastinal disorders/ Nasal congestion/ NASAL CONGESTION	•		HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081052; Age (Y Injury, poisoning and procedural complications/ Concussion/ MILD CONCUSSION	2020-10-12 (96)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 44 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/	Start Date and Time (Relative Day) / End Date and	cited	Sev.		- I	Other Action	Outcome
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081052; Age (Y Injury, poisoning and procedural complications/ Muscle strain/ NECK STRAIN (CAR ACCIDENT)	2020-10-12 (96)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-10-27 (111)/ 2020-11-16 (131)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 45 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011089; Age (Year Pregnancy, puerperium and perinatal conditions/ Abortion missed/ MISCARRIAGE (MISSED ABORTION)	ears): 32; Gender: F; 2021-02-26 (232)/ 2021-03-10 (244)	Race: W Yes/ Yes/ No	HITE 2	Yes/ 6	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021080; Age (You Gastrointestinal disorders/Abdominal discomfort/GASTROINTESTINAL DISTRESS (NOS)	•	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021151; Age (Young System disorders/Migraine/MIGRAINE		Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 46 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
	Start Date and	MAAE/		,		Action Taken	
System Organ Class/	Time (Relative Day)		_	SAE/	Relation-	- ,	
Preferred Term/ Verbatim	End Date and	cited AR	Sev.	Criteria	ship to IP/SP [3]	Other Action	0
	Time (Relative Day)		[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021151; Age (Ye Gastrointestinal disorders/ Nausea/ NAUSEA		Race: WI Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Vomiting/ VOMITING	2020-10-17 (101)/ 2020-10-19 (103)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Neck pain/ NECK PAIN	2020-10-17 (101)/ 2020-10-19 (103)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/Chills/CHILLS	2020-10-17 (101)/ 2020-10-19 (103)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 47 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021151; Age (Ye	ears): 30; Gender: F;	Race: W	HITE				
General disorders and administration site conditions/ Pyrexia/ FEVER	2020-10-18 (102)/ 2020-10-20 (104)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-10-18 (102)/ 2020-10-23 (107)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021154; Age (Ye	ears): 34; Gender: F;	Race: W	HITE				
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS RIGHT HAND	2020-12-15 (161)/ 2020-12-21 (167)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 48 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021164; Age (Year General disorders and administration site conditions/ Axillary pain/ UNDERARM TENDERNESS	Years): 34; Gender: F; 2020-06-14 (7)/ 2020-06-18 (11)	Race: W Yes/ Yes/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021180; Age (Yangury, poisoning and procedural complications/Muscle strain/BACK STRAIN	2020-07-29 (22)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031013; Age (Yanjury, poisoning and procedural complications/Meniscus injury/TORN MENISCUS RIGHT KNEE	2020-08-10 (42)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 49 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
_ ,	Start Date and	MAAE/		,		Action Taken	
System Organ Class/	Time (Relative Day)/		_	SAE/	Relation-	- ,	
Preferred Term/ Verbatim	End Date and	cited	Sev.	Criteria	ship to IP/SP [3]	Other Action	011+0000
	Time (Relative Day)	AR	[1]	[2]	1P/SP [3]	Taken	Outcome
Subject ID: US2031050; Age (Y Infections and infestations/ Influenza/ INFLUENZA A	ears): 51; Gender: F; 2021-02-21 (236)/ 2021-03-01 (244)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031079; Age (Y Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	ears): 34; Gender: F; 2020-07-30 (29)/ ONGOING	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Gastrointestinal disorders/ Intestinal obstruction/ INTESTINAL OBSTRUCTION	2020-11-13 (135)/ 2020-11-13 (135)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041046; Age (Y Infections and infestations/ Otitis media/ LEFT OTITIS MEDIA	ears): 23; Gender: M; 2020-10-14 (105)/ 2020-10-25 (116)	Race: Why Yes/Yes/No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 50 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041046; Age Infections and infestations/ Bronchitis/ BRONCHITIS	(Years): 23; Gender: M; 2020-11-06 (128)/ 2020-11-15 (137)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ WORSENING DEPRESSION	2020-12-02 (154)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Musculoskeletal and connective tissue disorders/ Muscle spasms/ LOW BACK SPASMS	2021-02-03 (217)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 51 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited		SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041061; Age Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	(Years): 52; Gender: F; 2020-07-06 (1)/ 2020-07-16 (11)		WHITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041080; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 26; Gender: F; 2021-01-02 (186)/ 2021-01-06 (190)		WHITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061023; Age General disorders and administration site conditions/ Axillary pain/ UNDERARM PAIN - LEFT ARM	(Years): 19; Gender: F; 2020-06-10 (6)/ 2020-06-12 (8)		BLACK (OR AFRICAN No	AMERICAN R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 52 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061023; Age (Psychiatric disorders/ Depression/ DEPRESSION	•		LACK O	R AFRICAN No	AMERICAN NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071002; Age (Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS ALL OVER BODY	Years): 39; Gender: F; 2020-07-01 08:00 (1), 2020-07-08 08:00 (8)		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-01 20:00 (2), 2020-07-12 08:00 (12)		1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 53 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071002; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 39; Gender: F; 2020-07-02 (3)/ 2020-08-02 (34)	Race: Wi Yes/ Yes/ Yes	HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-07-04 (5)/ 2020-07-09 (10)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081025; Age (Y Gastrointestinal disorders/ Haemorrhoids/ HEMORRHOIDS		Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 54 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081025; Age (Y Injury, poisoning and procedural complications/ Limb injury/ INJURY OF RIGHT PINKY FINGE	2020-09-22 (78)/ 2020-12-28 (175)	Race: Why Yes/Yes/No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinitis allergic/ ALLERGIC RHINITIS	2021-02-19 (228)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Eye disorders/ Conjunctivitis allergic/ ALLERGIC CONJUNCTIVITIS	2021-03-10 (247)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081063; Age (Yespeniatric disorders/Anxiety/ANXIETY	<pre>Zears): 22; Gender: M; 2020-10-12 (97)/ ONGOING</pre>	Race: WI Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 55 of 95
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/	Start Date and Time (Relative Day)/	TEAE/ MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081064; Age	(Years): 48; Gender: M;	Race: V	VHITE				
Infections and	2020-07-09 (1)/	Yes/	2	No	R/NR	DOSE NOT	RECOVERED/
infestations/	2020-07-10 (2)	Yes/				CHANGED/	RESOLVED
Gastroenteritis/		No				CONCOMITANT	
ACUTE GASTROENTERITIS						MEDICATION	

Notes listed on the last page.

Page 56 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011124; Age Infections and infestations/ Herpes simplex/ HERPES SIMPLEX II	(Years): 60; Gender: F; 2020-09-17 (56)/ 2020-10-01 (70)	Race: WHITE Yes/ 1 Yes/ No	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011131; Age Investigations/ Blood triglycerides increased/ HIGH TRIGLYCERIDES	(Years): 57; Gender: F; 2020-09-10 (49)/ ONGOING	Race: WHITE Yes/ 1 Yes/ No	No	NR/NR	NOT APPLICABLE/ NONE	NOT RECOVERED/ NOT RESOLVED
Skin and subcutaneous tissue disorders/ Hirsutism/ HIRSUTISM (UNWANTED HAIR GROWTH ON FACE)	2020-11-15 (115)/ ONGOING	Yes/ 1 Yes/ No	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 57 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2011142; Age (Y Gastrointestinal disorders/ Dental caries/ TOOTH EXTRACTION DENTAL CARIES	•		HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011156; Age (Y Investigations/ Blood cholesterol increased, WORSENING OF HIGH CHOLESTEROL	2020-11-03 (99)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2021021; Age (Y Musculoskeletal and connective tissue disorders/ Plantar fasciitis/ PLANAR FACSCITIS	ears): 71; Gender: M; 2020-08-25 (61)/ 2020-08-31 (67)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 58 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021043; Age (Y Immune system disorders/ Allergy to arthropod sting/ ALLERGIC REACTION WASP BITE	2020-06-16 (16)/ 2020-06-16 (16)	Race: V Yes/ Yes/ No	VHITE 3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021185; Age (Y Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	ears): 55; Gender: F; 2020-08-31 (32)/ 2020-08-31 (32)	Race: W Yes/ Yes/ No	VHITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED WITH SEQUELAE/ DUE TO SUBJECT BEING DIAGNOSIS IN 2000 BUT WAS NOT PRESCRIBED ANY MEDICATION. THIS WILL CONTINUE TO BE APART OF SUBJECT'S MEDICAL HISTORY
Infections and infestations/COVID-19/POSITIVE COVID-19 ILLNESS	2021-01-27 (181)/ 2021-02-12 (197)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 59 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021196; Age (Y Gastrointestinal disorders/Large intestine polyp/2 POLYPS COLON BENIGN	•	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021206; Age (Y Musculoskeletal and connective tissue disorders/ Exostosis/ BONE SPUR 2ND RIGHT TOE	ears): 64; Gender: F; 2020-07-08 (7)/ 2020-07-30 (29)	Race: Will Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Bursitis/ BURSITIS RIGHT HIP	2020-07-13 (12)/ 2020-07-16 (15)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 60 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021222; Infections and infestations/ Eye infection/ RIGHT EYE INFECTION	Age (Years): 65; Gender: F; 2020-12-23 (146)/ 2020-12-29 (152)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031129; Infections and infestations/ Sinusitis/ SINUSITIS	Age (Years): 61; Gender: M; 2020-08-23 (25)/ 2020-08-27 (29)	Race: WHITE Yes/ Yes/ No	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041114; Musculoskeletal and connective tissue disorders/ Back pain/ THORACIC BACK PAIN	Age (Years): 62; Gender: M; 2021-02-13 (195)/ 2021-02-19 (201)	Race: WHITE Yes/ 1 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 61 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041142; Age Metabolism and nutrition disorders/ Hypercholesterolaemia/ HYPERCHOLESTEROLEMIA	(Years): 63; Gender: M; 2021-01-27 (181)/ 2021-02-15 (200)	Race: WI Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041146; Age Infections and infestations/ Cellulitis/ CELLULITIS- RIGHT FOREARM	(Years): 59; Gender: F; 2020-07-05 (4)/ 2020-07-10 (9)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051063; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 56; Gender: M; 2020-12-10 (136)/ ONGOING	Race: Why Yes/Yes/No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 62 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]	Criteria s	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051072; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	e (Years): 69; Gender: M; 2020-08-24 (22)/ 2020-09-21 (50)	Race: WHITE Yes/ 2 Yes/ No	No N	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051112; Age Infections and infestations/ Gastroenteritis/ GASTROENTERITIS'	e (Years): 60; Gender: F; 2020-10-01 (60)/ 2020-10-16 (75)	Race: WHITE Yes/ 2 Yes/ No	No N	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061035; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	e (Years): 71; Gender: M; 2020-12-31 (165)/ 2021-01-17 (182)	Race: WHITE Yes/ Yes/ No	No N	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 63 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2061046; Age Infections and infestations/ Asymptomatic COVID-19/ ASYMPTOMATIC COVID-19	(Years): 62; Gender: F; 2020-12-15 (142)/ 2020-12-15 (142)	Race: WHITE Yes/ Yes/ No	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071005; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 56; Gender: F; 2020-11-22 (140)/ 2020-12-06 (154)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071041; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 64; Gender: M; 2020-09-27 (88)/ 2020-10-12 (103)	Race: WHITE Yes/ 3 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 64 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events

Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071086; Age Infections and infestations/ Viral upper respiratory tract infection/ VIRAL UPPER RESPIRATORY INFECTION	(Years): 68; Gender: M; 2020-11-09 (104)/ 2020-11-16 (111)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071088; Age Gastrointestinal disorder Gastrooesophageal reflux disease/ ACID REFLUX	s/ 2020-09-18 (54)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071092; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 61; Gender: F; 2020-11-20 (123)/ 2020-11-30 (133)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 65 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071092; Age (Infections and infestations/ Pneumonia/ PNEUMONIA	Years): 61; Gender: F; 2020-11-24 (127)/ 2020-11-30 (133)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071100; Age (Metabolism and nutrition disorders/ Hyperlipidaemia/ HYPERLIPIDEMIA	Years): 61; Gender: M; 2020-08-24 (21)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Psychiatric disorders/ Anxiety/ ANXIETY	2021-01-08 (158)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 66 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

	Start Date and	TEAE/ MAAE/				Action Taken	
System Organ Class/ Preferred Term/	Time (Relative Day)/ End Date and			SAE/ Criteria	Relation- ship to	with IP/ Other Action	
Verbatim	Time (Relative Day)	AR	[1] [[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071100; Age (Year Reproductive system and breast disorders/ Prostatomegaly/ ENLARGED PROSTATE		Race: WHI Yes/ Yes/ No		10	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
ubject ID: US2071103; Age (Young and the Company of				10	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081005; Age (Y- Skin and subcutaneous tissue disorders/ Angioedema/ SWOLLEN BLISTERED LIPS (INTERMITTENT ANGIOEDEMA)	ears): 55; Gender: F; 2020-06-09 (9)/ 2020-10-09 (131)	Race: WHI Yes/ Yes/ No		10	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 67 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081029; Age (YINvestigations/Computerised tomogram coronary artery abnormal/CORONARY CALCIUM SCAN ABNORMAL (ELEVATED)	<pre>/ears): 55; Gender: M; 2021-02-01 (210)/ ONGOING</pre>	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081077; Age (Y Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	<pre>//ears): 66; Gender: F; 2020-12-08 (128)/ 2020-12-19 (139)</pre>	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 68 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011040; Age (General disorders and administration site conditions/ Chest pain/ CHEST PAIN, UNKNOWN DETAIL	2020-06-02 22:49 (2) 2020-06-02 23:35 (2)	/ Yes/	BLACK (DR AFRICAN No	AMERICAN NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Metabolism and nutrition disorders/ Insulin resistance/ INSULIN RESISTANCE	2020-11-13 (138)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Investigations/ Hormone level abnormal/ LOW HORMONE LEVELS	2020-11-13 (138)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 69 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021004; Age Infections and infestations/ Cellulitis/ RIGHT FOOT CELLULITIS	(Years): 72; Gender: F; 2020-12-26 (184)/ 2021-01-03 (192)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021018; Age Musculoskeletal and connective tissue disorders/ Back pain/ WORSENING OF BACK PAIN	(Years): 71; Gender: F; 2020-08-04 (23)/ 2020-11-26 (137)	Race: WH Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021019; Age Skin and subcutaneous tissue disorders/ Rash/ RASH ON RIGHT KNEE NON-URTICARIAL	(Years): 59; Gender: M; 2020-06-01 (4)/ 2020-06-06 (9)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 70 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
System Organ Class/	Start Date and Time (Relative Day)/	MAAE/ Soli-		SAE/	Relation-	Action Taken with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021019; Age (Yenal and urinary disorders/ Nephrolithiasis/ NEPHROLITHIASIS (RIGHT)	<pre>%ears): 59; Gender: M; 2020-06-24 (27)/ 2020-07-06 (39)</pre>	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinitis allergic/ ALLERGIC RHINITIS	2021-01-22 (205)/ 2021-02-01 (215)	Yes/ Yes/ No	1	No	NR/NR	PROCEDURE DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021220; Age (Young Musculoskeletal and connective tissue disorders/ Tendonitis/ LEFT POSTERIOR TIBIAL TENDONITIS	<pre>%ears): 76; Gender: M; 2021-02-16 (203)/ 2021-03-15 (230)</pre>	Race: B Yes/ Yes/ No	LACK (OR AFRICAN No	AMERICAN NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 71 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2031097; Age (Ye Gastrointestinal disorders/Dental caries/TOOTH DECAY		Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Rotator cuff syndrome/ RIGHT ROTATOR CUFF TEAR	2020-08-24 (22)/ 2020-10-05 (64)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Cardiac disorders/ Acute myocardial infarction/ NON-ST ELEVATION MYOCARDIAL INFARCTION	2020-11-25 (115)/ 2020-11-25 (115)	Yes/ Yes/ No	2	Yes/ 3 (2020-11-25/ 2020-11-27)		NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Cerebrovascular accident/ CEREBRAL VASCULAR ACCIDENT	2020-12-01 (121)/ 2020-12-01 (121)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 72 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events

Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria		Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2031104; Age (Y Infections and infestations/ Tooth abscess/ ABSCESSED TOOTH	ears): 55; Gender: F; 2020-10-07 (69)/ 2020-10-07 (69)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2031108; Age (Y Gastrointestinal disorders/ Gastrooesophageal reflux disease/ ACID REFLUX		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031121; Age (Y Infections and infestations/ Oral candidiasis/ ORAL CANDIDIASIS	ears): 67; Gender: F; 2021-02-06 (194)/ 2021-02-23 (211)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 73 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2041103; Age (Ye	ears): 66; Gender: M;	Race: W	HITE				
Gastrointestinal disorders/ Oesophageal food impaction/ ESOPHAGEAL FOOD BOLUS OBSTRUCTION	2020-08-16 (24)/	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Gastrooesophageal reflux disease/ GASTROESOPHAGEAL REFLUX DISEASE	2020-08-28 (36)/ 2020-10-15 (84)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041104; Age (Ye	ears): 68; Gender: F;	Race: W	HITE				
Psychiatric disorders/ Insomnia/ INSOMNIA	2020-07-01 (6)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 74 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041109; Age (Y Infections and infestations/ Sinusitis/ SINUS INFECTION	Tears): 66; Gender: F; 2020-12-25 (152)/ 2021-01-05 (163)	Race: W Yes/ Yes/ No	VHITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041119; Age (Y Nervous system disorders/ Nervous system cyst/ CYST ON SPINAL NERVE		Race: W Yes/ Yes/ No	WHITE 1	Yes/ 3 (2020-11-16/ 2020-11-17)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Spondylolisthesis/ SPONDYLOLISTHESIS	2020-08-10 (7)/ 2020-11-16 (105)	Yes/ Yes/ No	1	Yes/ 3 (2020-11-16/ 2020-11-17)		NOT APPLICABLE/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Endocrine disorders/ Hypothyroidism/ HYPOTHYROIDISM	2020-11-11 (100)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 75 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events

Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041145; Age (Y Musculoskeletal and connective tissue disorders/ Arthritis/ RIGHT THUMB PIP ARTHRITIS	ears): 59; Gender: F; 2020-07-01 (-1)/ ONGOING	Race: W. No/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2041155; Age (Y Psychiatric disorders/ Depression/ DEPRESSION			HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051059; Age (Y Skin and subcutaneous tissue disorders/ Rash/ SKIN RASH LEFT CHEEK ON FAC (UNKNOWN ETIOLOGY)	2020-09-10 (46)/ 2020-10-31 (97)		HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 76 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]		Outcome
Subject ID: US2051059; Age ('Investigations/ Blood cholesterol increased HIGH CHOLESTEROL	2020-12-17 (144)/	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2051060; Age (Eye disorders/ Cataract/ CATARACT RIGHT EYE	Years): 65; Gender: F; 2020-10-09 (74)/ 2021-02-23 (211)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2051071; Age ('Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ ROTATOR CUFF PAIN	Years): 71; Gender: M; 2021-01-01 (159)/ 2021-02-08 (197)	Race: Will Yes/ Yes/ No	HITE 3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 77 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051092; Age (Y Injury, poisoning and procedural complications/ Muscle rupture/ TORN HAMSTRING RIGHT LEG	2020-11-10 (97)/	Race: W. Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2051095; Age (Y Infections and infestations/ Sinusitis/ SINUS INFECTION	ears): 58; Gender: F; 2020-11-05 (99)/ 2020-11-18 (112)	Race: W. Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051103; Age (Y Injury, poisoning and procedural complications/ Arthropod bite/ BUG BITE ON NECK	2020-07-03 (2)/	Yes/	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 78 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2061068; Age (Y	ears): 63; Gender: F;	Race: WH	HITE				
Nervous system disorders/	2020-07-31 08:35 (31)	/Yes/	2	No	NR/R	DOSE NOT	RECOVERED/
Dizziness/	2020-07-31 08:40 (31)	Yes/				CHANGED/	RESOLVED
DIZZINESS		No				NONE	
Psychiatric disorders/	2020-07-31 09:45 (31)	/Yes/	2	No	NR/R	DOSE NOT	RECOVERED/
Anxiety/	2020-07-31 14:30 (32)	Yes/				CHANGED/	RESOLVED
ANXIETY	. ,	No				NONE	
Subject ID: US2071083; Age (Y	ears): 87: Gender: F:	Race: WH	TTE				
Vascular disorders/	2020-09-03 (45)/	Yes/	1	No	NR/NR	DOSE NOT	NOT RECOVERED/
Hypertension/	ONGOING	Yes/			,	CHANGED/	NOT RESOLVED
HYPERTENSION		No				CONCOMITANT	
						MEDICATION	
Cardiac disorders/	2020-09-03 (45)/	Yes/	2	Yes/	NR/NR	NOT APPLICABLE/	RECOVERED/
Bradycardia/	2020-10-31 (103)	Yes/	_	3	1111, 1111	CONCOMITANT	RESOLVED
WORSENING OF BRADYCARDIA,	(100)	No		(2020-10-		PROCEDURE	
CHRONIC				30/			
				2020-10-3			
				1)			

Notes listed on the last page.

Page 79 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2071083; Age Psychiatric disorders/ Depression/ MILD DEPRESSION		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Cardiac disorders/ Diastolic dysfunction/ GRADE 1 DIASTOLIC DYSFUNCTION	2020-10-30 (102)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071104; Age Infections and infestations/ Bronchitis/ BRONCHITIS	(Years): 66; Gender: M; 2020-09-15 (37)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 80 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071106; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 64; Gender: M; 2020-07-11 (6)/ 2020-07-20 (15)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081003; Age Ear and labyrinth disorders/ Excessive cerumen production/ EAR WAX BUILD UP	(Years): 64; Gender: F; 2020-08-13 (46)/ 2020-08-13 (46)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Infections and infestations/ Fungal skin infection/ TOE FUNGUS (LEFT BIG TOE)	2020-12-03 (158)/ 2021-02-26 (243)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 81 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2081009; Age (Ye	ears): 59; Gender: F;	Race: W	HITE				
Skin and subcutaneous	2020-07-02 13:30 (1)		1	No	NR/NR	DOSE NOT	RECOVERED/
tissue disorders/	2020-07-09 (8)	Yes/				CHANGED/	RESOLVED
Dermatitis contact/		No				NONE	
CONTACT DERMATITIS							
Gastrointestinal disorders/	2020-09-30 (91)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERING/
Tongue discomfort/	ONGOING	Yes/				CHANGED/	RESOLVING
BURNING TONGUE SYNDROME		No				NONE	
Subject ID: US2081092; Age (Ye	ears): 77; Gender: F;	Race: W	HITE				
Skin and subcutaneous	2020-07-06 (5)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
tissue disorders/	2020-07-12 (11)	Yes/				CHANGED/	RESOLVED
Dermatitis/		No				NONE	
NONSPECIFIC DERMATITIS (RASH	ł						
ACROSS FOREHEAD AND UPPER							
BACK)							

Notes listed on the last page.

Page 82 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081100; Age Psychiatric disorders/ Anxiety/ WORSENING OF ANXIETY		Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081118; Age Renal and urinary disorders/ Hypertonic bladder/ OVERACTIVE BLADDER	(Years): 70; Gender: F; 2020-07-10 (10)/ ONGOING	Race: WHITE Yes/ Yes/ No	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081123; Age Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNI ACQUIRED)	2020-08-01 (33)/ 2020-08-26 (58)	Race: WHITE Yes/ 3 Yes/ No	Yes/ 2, 3 (2020-08-01/ 2020-08-05)		DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 83 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081123; Age (Y Investigations/ Blood alkaline phosphatase increased/ ELEVATED ALKALINE PHOSPHATASE	2020-08-11 (43)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Investigations/ Platelet count increased/ ELEVATED PLATELET COUNT	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 84 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011028; Age (Y Metabolism and nutrition disorders/ Gout/ GOUT, RIGHT GREAT TOE	Tears): 60; Gender: M; 2020-06-07 (7)/ 2020-06-16 (16)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Inguinal hernia/ HERNIA, LEFT INGUINAL	2020-10-30 (124)/ 2020-11-02 (127)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2011122; Age (Y Ear and labyrinth disorders/ Tinnitus/ TINNITUS, BILATERAL	Tears): 59; Gender: F; 2021-02-20 (212)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 85 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) End Date and Time (Relative Day)	TEAE/ MAAE/ / Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011162; Age (Note: Reproductive system and breast disorders/Breast pain/PAIN, RIGHT BREAST	Years): 62; Gender: F 2020-11-18 (108)/ 2021-01-20 (171)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Renal and urinary disorders/ Nephrolithiasis/ KIDNEY STONES	2021-01-18 (169)/ 2021-04-14 (255)	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Muscle strain/ PULLED MUSCLE, RIGHT PECTORAL	2021-01-20 (171)/ 2021-04-06 (247)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 86 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021003; Age (Y Renal and urinary disorders/ Haematuria/ HEMATURIA	ears): 58; Gender: M; 2020-10-06 (99)/ 2020-10-21 (114)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Metabolism and nutrition disorders/ Vitamin D deficiency/ VITAMIN D DEFICIENCY	2020-10-21 (114)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2021011; Age (Y Gastrointestinal disorders/ Diverticulum/ DIVERTICULOSIS		Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING
Eye disorders/ Glaucoma/ GLAUCOMA BILATERAL	2020-11-08 (136)/ 2020-11-08 (136)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED WITH SEQUELAE/ THIS WILL BE APART OF SUBJECT MEDICAL CONDITION

Notes listed on the last page.

Page 87 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021031; Age (Y Cardiac disorders/ Arrhythmia/ ARRHYTHMIA	Tears): 72; Gender: M; 2020-07-28 (30)/ 2020-07-30 (32)	Race: W Yes/ Yes/ No	HITE 4	Yes/ 3 (2020-07-28/ 2020-07-3 0)		NOT APPLICABLE/	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Struck by lightning/ STRUCK BY LIGHTNING	2020-07-28 (30)/ 2020-07-30 (32)	Yes/ Yes/ No	3	Yes/ 3 (2020-07- 28/ 2020-07-3 0)		NOT APPLICABLE/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021115; Age (Y Infections and infestations/ Otitis media/ RIGHT OTITIS MEDIA	Years): 59; Gender: F; 2021-02-14 (199)/ 2021-02-18 (203)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Acute sinusitis/ ACUTE SINUSITIS	2021-02-14 (199)/ 2021-02-28 (213)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 88 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day), End Date and Time (Relative Day)	TEAE/ MAAE/ / Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2021208; Age (Musculoskeletal and connective tissue disorders/ Plantar fasciitis/ PLANTAR FASCIITIS				No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021211; Age (Infections and infestations/ Tooth infection/ INFECTION FROM FILLING IN TOOTH	Years): 78; Gender: F; 2020-07-21 (20)/ 2020-07-27 (26)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders Gastrooesophageal reflux disease/ WORSENING OF GASTROESOPHAGEAL REFLUX DISEASE	2/ 2020-12-19 (142)/ 2020-12-20 (143)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 89 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	ship to	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021230; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 68; Gender: F; 2020-12-23 (143)/ 2021-02-05 (187)	Race: W. Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051108; Age Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS RIGHT FOREARM AND RIGHT THIGH	(Years): 65; Gender: M; 2020-07-16 (11)/ 2020-08-17 (43)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061036; Age Infections and infestations/ Nasopharyngitis/ COMMON COLD	(Years): 56; Gender: F; 2020-10-30 (96)/ ONGOING	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 90 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events

Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	-	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071013; Age (Y Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE WITHOUT DIAGNOSIS OF HYPERTENSION	2021-01-19 (195)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2071043; Age (Y Injury, poisoning and procedural complications/ Meniscus injury/ LEFT MEDIAL MENISCUS TEAR	2020-08-01 (27)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071082; Age (Y Skin and subcutaneous tissue disorders/ Erythema/ ERYTHEMA LEFT METATARSOPHALANGEAL JOINTS	ears): 57; Gender: M; 2020-08-18 (22)/ 2020-09-02 (37)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 91 of 95
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/			SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	-	Other Action	
<u>Verbatim</u>	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071082; Age (Yellow Musculoskeletal and connective tissue disorders/Arthralgia/TENDERNESS LEFT METATARSOPHALANGEAL JOINTS	<pre>Zears): 57; Gender: M; 2020-08-18 (22)/ 2020-09-02 (37)</pre>	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071087; Age (Y Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-09-28 (61)/ 2020-10-04 (67)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081014; Age (Y Injury, poisoning and procedural complications/ Concussion/ CONCUSSION	2020-08-22 (54)/	Race: W Yes/ Yes/ No	HITE 3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 92 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]		Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081016; Age ('Infections and infestations/Sinusitis/SINUS INFECTION	Years): 55; Gender: F; 2020-07-14 (16)/ 2020-07-23 (25)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081081; Age (Injury, poisoning and procedural complications/Tendon rupture/TORN ACHILLES (LEFT FOOT)	2021-01-06 (162)/	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Vascular disorders/ Hypertension/ HYPERTENSION	2021-01-27 (183)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 93 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081120; Age (Y Reproductive system and breast disorders/ Prostatomegaly/ ENLARGED PROSTATE	Tears): 72; Gender: M; 2020-12-01 (126)/ ONGOING	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2081129; Age (Y Nervous system disorders/ Dizziness/ DIZZINESS	· · · · · · · · · · · · · · · · · · ·		HITE 1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Malaise/ MALAISE	2020-08-10 (8)/ 2020-08-10 (8)	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 94 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events

Safety Set

Cohort 2 (Age \geq 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	ship to	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081129; Age (Sinjury, poisoning and procedural complications/ Chemical burn/ CHEMICAL BURN (MIDDLE STERNUM AND LEFT LATERAL SUPERIOR CHEST)	2020-12-08 (128)/	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

Notes listed on the last page.

Page 95 of 95 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date. MedDRA version $23.0\,$

- [1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.
- [2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.
- [3] R = Related, NR = Not Related, NA = Not Applicable.

ModernaTX, Inc.
mRNA-1273-P201 Part A end of

Part A end of Part A (Extraction Date: 11JUN2021)

Page 1 of 22

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) / End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021073; Age (Y Gastrointestinal disorders/Oral disorder/LESION ON GUM (UNKNOWN)BENGIN	ears): 51; Gender: F;			No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2020-12-05 (159)/ 2020-12-20 (174)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021082; Age (Y General disorders and administration site conditions/ Fatigue/ FATIGUE	ears): 47; Gender: M; 2020-09-06 (62)/ 2020-09-11 (67)	Race: Why Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 2 of 22
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day), End Date and Time (Relative Day)	TEAE/ MAAE/ 'Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021082; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 47; Gender: M; 2020-09-10 (66)/ 2020-10-08 (94)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood testosterone decreased/ LOW TESTOSTERONE	2020-10-15 (101)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Investigations/ Vitamin D decreased/ LOW VITAMIN D	2020-10-17 (103)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Endocrine disorders/ Hyperoestrogenism/ HYPERESTROGENISM	2020-12-14 (161)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

Notes listed on the last page.

Page 3 of 22
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					_
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2021094; Age (Y	ears): 53; Gender: M;	Race: W	HITE				
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-06-26 (22)/ 2020-08-08 (65)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Sinus headache/ SINUS HEADACHE	2020-06-29 (25)/ 2020-07-01 (27)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-06 (32)/ 2020-07-23 (49)	Yes/ Yes/ No	2	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 4 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
<pre>Subject ID: US2021137; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)</pre>	(Years): 26; Gender: M; 2020-07-07 15:39 (29) 2020-07-15 14:00 (37)	/Yes/	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021155; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 46; Gender: M; 2020-08-17 (36)/ 2020-09-23 (73)	Race: W Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021175; Age General disorders and administration site conditions/ Fatigue/ FATIGUE	(Years): 36; Gender: F; 2020-07-08 21:31 (1), 2020-07-17 14:13 (10)	/ Yes/	HITE 3	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 5 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021175; Age (Y Nervous system disorders/ Headache/ HEADACHE	•	Race: WI Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2020-10-12 (97)/ 2020-11-01 (117)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031081; Age (Y Infections and infestations/ COVID-19/ COVID 19 INFECTION	ears): 36; Gender: F; 2020-08-03 (33)/ 2020-08-03 (33)		HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 6 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041022; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 40; Gender: F; 2020-10-31 (118)/ 2020-11-15 (133)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051035; Age Infections and infestations/ COVID-19/ POSITIVE COVID 19 INFECTI	2020-09-03 (58)/ 2021-03-26 (262)		HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061003; Age Infections and infestations/ COVID-19/ COVID - 19 INFECTION	(Years): 35; Gender: F; 2021-01-06 (185)/ 2021-01-16 (195)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 7 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2061018; Age (Years): 50; Gender: F;	Race: W	HITE				
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-11-28 (144)/ 2020-12-01 (147)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID-19 POSITIVE INFECTION	2020-12-01 (147)/ 2020-12-05 (151)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071012; Age (Yange Infections and infestations/COVID-19/COVID 19 INFECTION	Years): 40; Gender: F; 2020-12-04 (151)/ 2020-12-16 (163)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 8 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

		TEAE/					
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071050; Age ((Years): 45; Gender: M;	Race: W	HITE				
Infections and	2020-12-04 (151)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2020-12-14 (161)	Yes/				CHANGED/	RESOLVED
Gingivitis/		No				CONCOMITANT	
GINGIVITIS						MEDICATION	
Infections and	2020-12-04 (151)/	Yes/	2	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2020-12-18 (165)	Yes/				CHANGED/	RESOLVED
COVID-19/		No				CONCOMITANT	
COVID 19 INFECTION						MEDICATION	
Subject ID: US2071062; Age (Years): 29; Gender: M;	Race: W	HITE				
Skin and subcutaneous	2020-06-05 (2)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
tissue disorders/	2020-06-06 (3)	No/				CHANGED/	RESOLVED
Rash/		No				NONE	
RASH ON GLUTEUS							

Notes listed on the last page.

ModernaTX, Inc.

Page 9 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]		ship to	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071062; Ac Infections and infestations/ COVID-19/ COVID-19 INFECTION	re (Years): 29; Gender: M; 2020-11-24 (141)/ 2020-11-30 (147)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071070; Ac Infections and infestations/ COVID-19/ COVID 19 INFECTION	re (Years): 34; Gender: F; 2020-12-11 (158)/ 2021-02-02 (211)	Race: WHITE Yes/ 2 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071072; Ac Infections and infestations/ COVID-19/ COVID 19 INFECTION	re (Years): 39; Gender: F; 2020-11-30 (148)/ 2020-12-11 (159)	Race: WHITE Yes/ 1 Yes/ No	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.
mRNA-1273-P201 Part A end of Part A (Extract

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081033; Age (Y Infections and infestations/ Otitis externa/ SWIMMER'S EAR (LEFT EAR)	ears): 43; Gender: F; 2020-07-13 (7)/ 2020-07-18 (12)	Race: WH Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2021-01-05 (183)/ 2021-03-15 (252)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081046; Age (Y Skin and subcutaneous tissue disorders/ Rash papular/ PAPULAR RASH ON FOREARM (BILATERAL)	ears): 45; Gender: M; 2020-06-08 (1)/ 2020-06-16 (9)	Race: Wi Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Program: \Moderna MODMRNA1273P201\Part A end of Part A\TLF\l16020712.sas 19JUL2021 20:33 Database Lock Date: 10JUN2021

Page 10 of 22

ModernaTX, Inc.

Page 11 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081046; Age (Infections and infestations/COVID-19/CONFIRMED COVID 19 INFECTION (SYMPTOMATIC-FEVER, HEADACHE, HEAVY FEELING IN CHEST, BODY ACHES)	2020-10-06 (90)/ 2020-11-06 (121)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.
mRNA-1273-P201 Part A en

Part A end of Part A (Extraction Date: 11JUN2021)

Page 12 of 22

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]			Outcome
Subject ID: US2041016; Age () Infections and infestations/ Viral infection/ VIRAL SYNDROME OF UNKNOWN ETIOLOGY	Years): 39; Gender: M; 2020-12-09 (149)/ 2021-01-21 (192)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NA	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041047; Age (Infections and infestations/COVID-19/COVID-19 INFECTION	Years): 33; Gender: M; 2020-08-04 (36)/ 2020-08-13 (45)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081036; Age (Nervous system disorders/Migraine/WORSENING OF MIGRAINES		Race: W. Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 13 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2081036; Age Infections and infestations/COVID-19/COVID 19 INFECTION	(Years): 48; Gender: M; 2020-12-15 (160)/ 2020-12-25 (170)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 14 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)		Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2041080; Age Infections and infestations/COVID-19/COVID-19 INFECTION	(Years): 26; Gender: F; 2021-01-02 (186)/ 2021-01-06 (190)	Race: W Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 15 of 22 Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021185; Age (Y Reproductive system and breast disorders/ Postmenopausal haemorrhage/ POSTMENOPAUSAL BLEEDING	ears): 55; Gender: F; 2020-07-04 (9)/ 2020-07-11 (16)	Race: W Yes/ No/ No	HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	2020-08-31 (32)/ 2020-08-31 (32)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED WITH SEQUELAE/ DUE TO SUBJECT BEING DIAGNOSIS IN 2000 BUT WAS NOT PRESCRIBED ANY MEDICATION. THIS WILL CONTINUE TO BE APART OF SUBJECT'S MEDICAL HISTORY
Infections and infestations/ COVID-19/ POSITIVE COVID-19 ILLNESS	2021-01-27 (181)/ 2021-02-12 (197)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 16 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited Sev. AR [1]	_	- ,	Outcome
Subject ID: US2031102; A Infections and infestations/ COVID-19/ COVID 19 INFECTION	Age (Years): 57; Gender: F; 2020-08-28 (26)/ 2020-08-28 (26)	Race: WHITE Yes/ 1 No/ No	No NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051063; A Infections and infestations/ COVID-19/ COVID-19 INFECTION	Age (Years): 56; Gender: M; 2020-12-10 (136)/ ONGOING	Race: WHITE Yes/ 1 Yes/ No	No NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2051072; A Infections and infestations/ COVID-19/ COVID-19 INFECTION	Age (Years): 69; Gender: M; 2020-08-24 (22)/ 2020-09-21 (50)	Race: WHITE Yes/ 2 Yes/ No	No NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 17 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061035; Age Investigations/ Heart rate decreased/ DECREASED HEART RATE	(Years): 71; Gender: M; 2020-06-26 13:41 (1), 2020-06-26 19:00 (1)		HITE 1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/COVID-19/COVID-19 INFECTION	2020-12-31 (165)/ 2021-01-17 (182)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061046; Age Infections and infestations/ Asymptomatic COVID-19/ ASYMPTOMATIC COVID-19	(Years): 62; Gender: F; 2020-12-15 (142)/ 2020-12-15 (142)	Race: War Yes/ Yes/ No	HITE 1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 18 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev.	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071005; Age Infections and infestations/ COVID-19/ COVID-19 INFECTION	(Years): 56; Gender: F; 2020-11-22 (140)/ 2020-12-06 (154)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071041; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 64; Gender: M; 2020-09-27 (88)/ 2020-10-12 (103)		HITE 3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071092; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 61; Gender: F; 2020-11-20 (123)/ 2020-11-30 (133)	Race: Wi Yes/ Yes/ No	HITE 2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

ModernaTX, Inc.

Page 19 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	cited	Sev.	SAE/ Criteria	Relation- ship to IP/SP [3]	Other Action	Outcome
Subject ID: US2071092; Age Infections and infestations/				No	NR/NR	DOSE NOT	RECOVERED/ RESOLVED
Pneumonia/ PNEUMONIA	2020 11 30 (133)	No				CONCOMITANT MEDICATION	KESOUVED

Notes listed on the last page.

ModernaTX, Inc.

Page 20 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 μg

		TEAE/	•				
	Start Date and	MAAE/				Action Taken	
System Organ Class/	Time (Relative Day)/	Soli-		SAE/	Relation-	with IP/	
Preferred Term/	End Date and	cited	Sev.	Criteria	ship to	Other Action	
Verbatim	Time (Relative Day)	AR	[1]	[2]	IP/SP [3]	Taken	Outcome
Subject ID: US2071106; Age	(Years): 64; Gender: M;	Race: W	HITE				
Infections and	2020-07-11 (6)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
infestations/	2020-07-20 (15)	Yes/				CHANGED/	RESOLVED
COVID-19/		No				CONCOMITANT	
COVID 19 INFECTION						MEDICATION	

Notes listed on the last page.

ModernaTX, Inc.

Page 21 of 22
mRNA-1273-P201

Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 μg

Custom Ourser Class/	Start Date and	TEAE/ MAAE/		SAE/	Relation-	Action Taken	
System Organ Class/ Preferred Term/	Time (Relative Day)/ End Date and	Soli- cited	Sev.	Criteria		Other Action	
Verbatim		AR	[1]	[2]	IP/SP [3]		Outcome
Subject ID: US2021230; Age Infections and infestations/ COVID-19/ COVID 19 INFECTION	(Years): 68; Gender: F; 2020-12-23 (143)/ 2021-02-05 (187)	Race: W Yes/ Yes/ No	NHITE 2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

Notes listed on the last page.

Page 22 of 22
Part A end of Part A (Extraction Date: 11JUN2021)

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date. MedDRA version $23.0\,$

- [1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.
- [2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.
- [3] R = Related, NR = Not Related, NA = Not Applicable.